<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">92762</article-id><article-id pub-id-type="doi">10.7554/eLife.92762</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Recording and classifying MET receptor mutations in cancers</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-329636"><name><surname>Guérin</surname><given-names>Célia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-148706"><name><surname>Tulasne</surname><given-names>David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6764-7242</contrib-id><email>david.tulasne@cnrs.fr</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05k9skc85</institution-id><institution>Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020 – UMR1277 - Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies</institution></institution-wrap><addr-line><named-content content-type="city">Lille</named-content></addr-line><country>France</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Dötsch</surname><given-names>Volker</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04cvxnb49</institution-id><institution>Goethe University</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>04</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e92762</elocation-id><history><date date-type="received" iso-8601-date="2023-09-14"><day>14</day><month>09</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2024-04-04"><day>04</day><month>04</month><year>2024</year></date></history><permissions><copyright-statement>© 2024, Guérin and Tulasne</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Guérin and Tulasne</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-92762-v1.pdf"/><abstract><p>Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This success is the consequence of a long characterization of MET mutations in cancers, which we propose to outline in this review. MET, a receptor tyrosine kinase (RTK), displays in a broad panel of cancers many deregulations liable to promote tumour progression. The first MET mutation was discovered in 1997, in hereditary papillary renal cancer (HPRC), providing the first direct link between MET mutations and cancer development. As in other RTKs, these mutations are located in the kinase domain, leading in most cases to ligand-independent MET activation. In 2014, novel MET mutations were identified in several advanced cancers, including lung cancers. These mutations alter splice sites of exon 14, causing in-frame exon 14 skipping and deletion of a regulatory domain. Because these mutations are not located in the kinase domain, they are original and their mode of action has yet to be fully elucidated. Less than five years after the discovery of such mutations, the efficacy of a MET TKI was evidenced in NSCLC patients displaying MET exon 14 skipping. Yet its use led to a resistance mechanism involving acquisition of novel and already characterized MET mutations. Furthermore, novel somatic MET mutations are constantly being discovered. The challenge is no longer to identify them but to characterize them in order to predict their transforming activity and their sensitivity or resistance to MET TKIs, in order to adapt treatment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>receptor tyrosine kinase</kwd><kwd>mutation</kwd><kwd>targeted therapies</kwd><kwd>cancer</kwd></kwd-group><funding-group><funding-statement>No external funding was received for this work.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Classification of MET mutations allows a better understanding of sensitivity and resistance to targeted therapies used in cancer.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>MET is a RTK expressed mainly in epithelial cells and activated by its high-affinity ligand, hepatocyte growth factor (HGF). MET activation by HGF promotes a program known as invasive growth, comprising cell division, cell motility, extracellular matrix digestion, invasion, survival, and morphogenic differentiation (<xref ref-type="bibr" rid="bib8">Bardelli et al., 1997a</xref>; <xref ref-type="bibr" rid="bib114">Tamagnone and Comoglio, 1997</xref>; <xref ref-type="bibr" rid="bib101">Rubin et al., 1993</xref>). In an organism, the MET/HGF pair is involved in many processes, including embryonic development (<xref ref-type="bibr" rid="bib11">Bladt et al., 1995</xref>; <xref ref-type="bibr" rid="bib102">Schmidt et al., 1995</xref>; <xref ref-type="bibr" rid="bib123">Uehara et al., 1995</xref>; <xref ref-type="bibr" rid="bib75">Maina et al., 1996</xref>), development of specific organs/tissues such as the placenta, liver, lung, and muscle (<xref ref-type="bibr" rid="bib11">Bladt et al., 1995</xref>; <xref ref-type="bibr" rid="bib102">Schmidt et al., 1995</xref>; <xref ref-type="bibr" rid="bib129">Woolf et al., 1995</xref>; <xref ref-type="bibr" rid="bib131">Yang et al., 1995</xref>), and tissue regeneration (<xref ref-type="bibr" rid="bib77">Matsumoto and Nakamura, 1992</xref>).</p><p>MET is synthesized as a precursor which matures through proteolytic cleavage. This leads to the formation of a heterodimeric receptor composed of an extracellular part, containing a SEMA domain, a PSI domain, and four immunoglobulin plexin transcription factor (IPT) domains, and an intracellular part, containing a juxtamembrane domain (JM), a tyrosine kinase domain (TKD), and a C-terminal tail (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib109">Stella and Comoglio, 1999</xref>; <xref ref-type="bibr" rid="bib30">Fernandes et al., 2019</xref>; <xref ref-type="bibr" rid="bib82">Montagne et al., 2014</xref>).</p><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>List of MET mutations found within the functional domains of the receptor.</title><p>The extracellular portion of MET consists of the SEMA domain, a PSI domain, and four immunoglobulin-plexin-transcription (IPT) repeats; the intracellular region contains the juxtamembrane domain, the tyrosine kinase domain, and the carboxyterminal docking site. The cancer types in which particular mutations have been identified are noted in parentheses: breast cancer (BC), cancer of unknown primary origin (CUP), colorectal cancer (CRC), gastric cancer (GC), hepatocellular carcinoma (HCC), hereditary papillary renal carcinoma (HPRC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), sporadic papillary renal carcinoma (SPRC), malignant pleural mesothelioma (MPM), oropharyngeal squamous cell carcinoma (OSCC), and metastasis (Meta). It is worth noting that the amino acid positions are annotated from MET transcript variant 1 NM_001127500.3 (<xref ref-type="bibr" rid="bib119">Tovar and Graveel, 2017</xref>; <xref ref-type="bibr" rid="bib73">Ma et al., 2005</xref>; <xref ref-type="bibr" rid="bib72">Ma et al., 2003</xref>; <xref ref-type="bibr" rid="bib68">Liu et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Jardim et al., 2014</xref>; <xref ref-type="bibr" rid="bib110">Stella et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Jagadeeswaran et al., 2006</xref>; <xref ref-type="bibr" rid="bib84">Moon et al., 2000</xref>; <xref ref-type="bibr" rid="bib91">Park et al., 1999</xref><xref ref-type="bibr" rid="bib7">Bahcall et al., 2016</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92762-fig1-v1.tif"/></fig><p>HGF, the high-affinity ligand of MET, is a 90 kDa heterodimeric protein composed of an α subunit with an N domain and four loop domains (domains k1 to k4) and a β chain displaying homology to a serine protease domain (SPH) but lacking catalytic activity (<xref ref-type="bibr" rid="bib38">Gherardi et al., 2003</xref>). The HGF/MET interaction is ensured by binding the SPH and k1 domains of HGF to the SEMA domain of MET (<xref ref-type="bibr" rid="bib39">Gherardi et al., 2006</xref>; <xref ref-type="bibr" rid="bib122">Uchikawa et al., 2021</xref>). However, HGF/MET cryo-EM structure resolutions allow the proposing of different scenarios for MET dimerization. First, MET dimerization could be ensured by HGF dimerization via a top-to-tail interaction of N and k1. This would lead to the association of two MET receptors, each interacting with an HGF. This 2:2 model of interaction suggests a symmetric HGF/MET structure (<xref ref-type="bibr" rid="bib39">Gherardi et al., 2006</xref>). Second, in a recent study, it has been proposed that one HGF can bind two MET receptors, one through the SPH domain and one through the k1 domain, this leading to MET dimerization. This asymmetric 2:1 model could be further stabilized by heparin and/or binding of a second HGF to the second MET receptor (<xref ref-type="bibr" rid="bib122">Uchikawa et al., 2021</xref>).</p><p>Once the MET receptor interacts with its ligand, it undergoes phosphorylation on two residues of the catalytic domain (Y1252/Y1253 or Y1234/Y1235 in the short MET isoform). It is worth noting that all the mentioned amino acid positions are annotated from the long isoform of MET (MET transcript variant 1 NM_001127500.3). The positions of some amino acids are also mentioned on the basis of the short isoform, as a reminder of the initial publication. Subsequently, other residues outside the catalytic domain are phosphorylated, including residue Y1367/Y1374 (Y1349/Y1356 in the short isoform) in the C-terminal tail, called the multi-substrate docking site (<xref ref-type="bibr" rid="bib69">Longati et al., 1994</xref>; <xref ref-type="bibr" rid="bib97">Ponzetto et al., 1994</xref>), as phosphorylated tyrosines in the C-terminal tail are able to recruit multiple effectors such as GRB2-associated binder-1 (GAB1), growth factor receptor–bound protein-2 (GRB2), SRC homology 2 domain-containing (SHC), phosphoinositide 3 kinase (PI3K), non-receptor tyrosine kinase SRC, signal transducer and activator of transcription 3 (STAT3), and phospholipase C-gamma (PLCγ). This multisubstrate docking site plays a key role in the induction by MET of intracellular signalling pathways and biological responses including survival, motility, invasion, and cell cycle progression (<xref ref-type="fig" rid="fig1">Figure 1</xref>; <xref ref-type="bibr" rid="bib96">Ponzetto et al., 1993</xref>; <xref ref-type="bibr" rid="bib17">Chiara et al., 2003</xref>; <xref ref-type="bibr" rid="bib99">Rhoades Smith and Bilen, 2019</xref>). In parallel, MET signalling is downregulated by the juxtamembrane region of the cytoplasmic part of the receptor, encoded by exon 14 with its phosphorylated Tyr1021 (Tyr1003 in the short MET isoform) (<xref ref-type="bibr" rid="bib21">Cortot et al., 2017</xref>).</p></sec><sec id="s2"><title>Multiple mechanisms of MET activation in cancer</title><p>To date, four main genomic events have been described that lead to MET activation and oncogene-driven tumorigenesis (<xref ref-type="bibr" rid="bib27">Duplaquet et al., 2018</xref>). First, MET gene amplification or copy number gain (CNG), leading to MET overexpression and its ligand-independent activation, has been identified as responsible for carcinogenesis in several tumour types including glioblastoma (<xref ref-type="bibr" rid="bib15">Cancer Genome Atlas Research Network, 2023</xref>), lung adenocarcinoma (LUAD) (<xref ref-type="bibr" rid="bib20">Collisson et al., 2014</xref>), gastric cancer (GC) (<xref ref-type="bibr" rid="bib3">Asaoka et al., 2010</xref>), colorectal cancer (CRC) (<xref ref-type="bibr" rid="bib125">Umeki et al., 1999</xref>), and medulloblastoma (<xref ref-type="bibr" rid="bib118">Tong et al., 2004</xref>). The phenomenon was observed for the first time in gastric carcinoma, where MET overexpression caused by gene amplification led to its activation and to the transformation of several cell lines (<xref ref-type="bibr" rid="bib95">Ponzetto et al., 1991</xref>). Second, HGF overexpression has been observed in breast, gastric, colon, and lung cancers and leads to aberrant MET activation through establishment of an autocrine loop (<xref ref-type="bibr" rid="bib124">Ujiie et al., 2012</xref>). The third mechanism, found in a limited number of tumours, is chromosomal rearrangement leading to MET fusion with another gene. This leads notably to constitutive MET activation or overexpression and involves fusions including KIF5B-MET in LUAD and BAIAP2L1-MET and C8ORF34-MET in RCC (<xref ref-type="bibr" rid="bib111">Stransky et al., 2014</xref>). The fourth type of genomic event responsible for MET activation is MET-activating mutations, which constitute the main focus of this review. Since the first MET mutation was discovered in HPRC in 1997 (<xref ref-type="bibr" rid="bib103">Schmidt et al., 1997</xref>), many MET mutations have been identified. The majority of MET mutations were found in papillary renal cancer and are located in the tyrosine kinase domain of MET. Over the last decade, however, other mutations have been identified outside the kinase domain. In NSCLC, for instance, missense mutations have been found in the SEMA and JM domains, in addition to a large panel of mutations leading to exon 14 skipping (<xref ref-type="bibr" rid="bib119">Tovar and Graveel, 2017</xref>; <xref ref-type="bibr" rid="bib73">Ma et al., 2005</xref>; <xref ref-type="bibr" rid="bib72">Ma et al., 2003</xref>; <xref ref-type="bibr" rid="bib58">Krishnaswamy et al., 2009</xref>; <xref ref-type="bibr" rid="bib106">Schrock et al., 2016</xref>; <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). Despite all the MET mutations already identified, novel MET mutations are constantly being discovered (<xref ref-type="bibr" rid="bib107">Sebai et al., 2022</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Recording of MET mutations found in cancers (<xref ref-type="bibr" rid="bib119">Tovar and Graveel, 2017</xref>; <xref ref-type="bibr" rid="bib73">Ma et al., 2005</xref>; <xref ref-type="bibr" rid="bib72">Ma et al., 2003</xref>; <xref ref-type="bibr" rid="bib68">Liu et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Jardim et al., 2014</xref>; <xref ref-type="bibr" rid="bib110">Stella et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Jagadeeswaran et al., 2006</xref>; <xref ref-type="bibr" rid="bib84">Moon et al., 2000</xref>; <xref ref-type="bibr" rid="bib91">Park et al., 1999</xref>; <xref ref-type="bibr" rid="bib7">Bahcall et al., 2016</xref>).</title><p>In this table, recording the MET mutations characterized by functional studies, subdomain localization of MET mutations were indicated as well as their sensitivity to hepatocyte growth factor (HGF) stimulation and the cancer type in which they were identified. The type of functional assay performed to identify them as activating mutations is indicated.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle">Domain</th><th align="left" valign="middle">Subdomain</th><th align="left" valign="middle">AA</th><th align="left" valign="middle">Cancer</th><th align="left" valign="middle">Functional assay</th><th align="left" valign="middle">Sensitivity to HGF</th><th align="left" valign="middle">References</th></tr></thead><tbody><tr><td align="left" valign="middle">Extracellular</td><td align="left" valign="middle">SEMA</td><td align="left" valign="middle">H150Y</td><td align="left" valign="middle">CUP</td><td align="left" valign="middle">Anchorage-independent growth assay</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib110">Stella et al., 2011</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">E168D</td><td align="left" valign="middle">NSCLC, SCLC, BC, CUP</td><td align="left" valign="middle">BaF3 cells, soft agar colony assay SCLC H446</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib72">Ma et al., 2003</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">N375S</td><td align="left" valign="middle">NSCLC, SCLC, BC, CRC</td><td align="left" valign="middle">Cell migration, invasion, and colony-forming assay, tumor growth study after cell xenograft</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib73">Ma et al., 2005</xref>; <xref ref-type="bibr" rid="bib50">Jardim et al., 2014</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">C385Y</td><td align="left" valign="middle">CUP</td><td align="left" valign="middle">Anchorage-independent growth assay</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib110">Stella et al., 2011</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">M431V</td><td align="left" valign="middle">Malignant pleural mesothelioma (MPM)</td><td align="left" valign="middle">Cell migration and motility assay</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib47">Jagadeeswaran et al., 2006</xref></td></tr><tr><td align="left" valign="middle">Juxtamembrane</td><td align="left" valign="middle"/><td align="left" valign="middle">R988C</td><td align="left" valign="middle">NSCLC, SCLC</td><td align="left" valign="middle">BaF3 cells, soft agar colony assay SCLC H446</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib72">Ma et al., 2003</xref>; <xref ref-type="bibr" rid="bib83">Montagne et al., 2017</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">P1009S</td><td align="left" valign="middle">GC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib62">Lee et al., 2000</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">T1010I</td><td align="left" valign="middle">NSCLC, SCLC, BC, CRC, CUP</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib62">Lee et al., 2000</xref></td></tr><tr><td align="left" valign="middle">Kinase N-lobe</td><td align="left" valign="middle"/><td align="left" valign="middle">H1086L</td><td align="left" valign="middle">HPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib107">Sebai et al., 2022</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">P-Loop</td><td align="left" valign="middle">I1102T</td><td align="left" valign="middle">HPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib107">Sebai et al., 2022</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">P-Loop</td><td align="left" valign="middle">N1118Y</td><td align="left" valign="middle">Metastasis</td><td align="left" valign="middle">Cell migration and invasion assay</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib70">Lorenzato et al., 2002</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">P-Loop</td><td align="left" valign="middle">C1125G</td><td align="left" valign="middle">HPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib107">Sebai et al., 2022</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">P-Loop</td><td align="left" valign="middle">L1130S</td><td align="left" valign="middle">HPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib107">Sebai et al., 2022</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">M1149T</td><td align="left" valign="middle">HPRC/SPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref></td></tr><tr><td align="left" valign="middle">Kinase C-lobe</td><td align="left" valign="middle"/><td align="left" valign="middle">V1206L</td><td align="left" valign="middle">HPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">L1213V</td><td align="left" valign="middle">SPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">Activation Loop (1231–1262)</td><td align="left" valign="middle">V1238I</td><td align="left" valign="middle">HPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">Activation Loop (1231–1262)</td><td align="left" valign="middle">D1246N/H/V</td><td align="left" valign="middle">HPRC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref>; <xref ref-type="bibr" rid="bib7">Bahcall et al., 2016</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">Activation Loop (1231–1262)</td><td align="left" valign="middle">Y1248C/D/H</td><td align="left" valign="middle">HPRC, SPRC, OSCC, HNSCC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle">Yes</td><td align="left" valign="middle"><xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">Activation Loop (1231–1262)</td><td align="left" valign="middle">Y1253D</td><td align="left" valign="middle">OSCC, HNSCC, BC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib10">Bardelli et al., 1998</xref>; <xref ref-type="bibr" rid="bib68">Liu et al., 2015</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle">COOH-terminal lobe of the kinase domain</td><td align="left" valign="middle">M1268T/I</td><td align="left" valign="middle">HPRC, SPRC, HCC</td><td align="left" valign="middle">Focus formation NIH3T3</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref></td></tr><tr><td align="left" valign="middle"/><td align="left" valign="middle"/><td align="left" valign="middle">V1312I</td><td align="left" valign="middle">CUP</td><td align="left" valign="middle">Anchorage-independent growth assay</td><td align="left" valign="middle"/><td align="left" valign="middle"><xref ref-type="bibr" rid="bib110">Stella et al., 2011</xref></td></tr></tbody></table></table-wrap></sec><sec id="s3"><title>MET kinase domain mutations in papillary renal cancer</title><p>Despite the numerous deregulations described previously, no direct causal link between MET and cancer progression was evidenced until 1997, when MET-activating mutations were found in HPRC and associated with cancer progression (<xref ref-type="bibr" rid="bib103">Schmidt et al., 1997</xref>). Renal cell carcinoma is the most common type of kidney cancer in adults. It is a heterogeneous disease composed of multiple subtypes, such as clear cell renal cell carcinoma (80% of RCCs) and non-clear cell renal cell carcinoma, of which the most common subtype is papillary renal cell carcinoma (15–20% of RCCs). Papillary renal cell carcinoma (PRCC) is divided into two subtypes: type I and II, distinguished histologically, type II being the hereditary form (<xref ref-type="bibr" rid="bib99">Rhoades Smith and Bilen, 2019</xref>; <xref ref-type="bibr" rid="bib78">Mendhiratta et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Akhtar et al., 2019</xref>). Interestingly, HPRC is the first cancer in which MET mutations, segregating from generation to generation, were identified as causal. The first direct link between MET mutations and cancer development was established in 1997 through genomic polymorphism analysis by Schmidt et al., who found the disease to segregate with a locus on chromosome 7q, carrying the MET proto-oncogene. Chromosome-7 duplication, rather than the loss at this location, suggested the involvement of an oncogene suspected of being MET (<xref ref-type="bibr" rid="bib103">Schmidt et al., 1997</xref>). In addition, because MET belongs to the same family (the receptor tyrosine kinase family) as RET, a proto-oncogene already known to be mutated in other inherited cancer syndromes (<xref ref-type="bibr" rid="bib21">Cortot et al., 2017</xref>), the MET proto-oncogene was sequenced rather than the two other genes also found at this locus. Through analysis of nine families affected by papillary renal carcinoma and sporadic papillary renal carcinoma, missense mutations of MET were identified, all located in the kinase domain, among which germline mutations (M1149T, V1206L, V1238I, D1246N, and Y1248C) and somatic mutations (D1246H, Y1228C, and M1268T) (<xref ref-type="bibr" rid="bib103">Schmidt et al., 1997</xref>; <xref ref-type="bibr" rid="bib104">Schmidt et al., 1999</xref>).</p></sec><sec id="s4"><title>Consequences of these MET kinase domain mutations</title><p>Following this initial identification, several functional studies were performed. Biochemical and biological assays on murine fibroblasts transfected with MET cDNA demonstrated an increase in MET autophosphorylation when mutations were inserted, demonstrating that these are able to cause constitutive activity of the MET receptor (<xref ref-type="bibr" rid="bib119">Tovar and Graveel, 2017</xref>; <xref ref-type="bibr" rid="bib9">Bardelli et al., 1997b</xref>; <xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib10">Bardelli et al., 1998</xref>; <xref ref-type="bibr" rid="bib41">Graveel et al., 2004</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref>). Interestingly, different levels of tyrosine kinase activity were observed according to the mutation (<xref ref-type="bibr" rid="bib52">Jeffers et al., 1998</xref>), M1268T substitutions being identified as the most active, followed by Y1248H, L1213V, and D1246H (<xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="table" rid="table1">Table 1</xref>). Next, analysis of focus formation, cell motility, and tumour growth in athymic mice demonstrated a correlation between MET enzymatic activity and the transforming properties of the different mutants (<xref ref-type="bibr" rid="bib8">Bardelli et al., 1997a</xref>; <xref ref-type="bibr" rid="bib103">Schmidt et al., 1997</xref>; <xref ref-type="bibr" rid="bib10">Bardelli et al., 1998</xref>; <xref ref-type="bibr" rid="bib41">Graveel et al., 2004</xref>). For instance M1268T, the most active mutant, elicited the most marked focus formation (<xref ref-type="bibr" rid="bib10">Bardelli et al., 1998</xref>). The involvement of HGF stimulation was also investigated. The two most strongly activating variants, M1268T and Y1248H, displayed constitutive activity, being found to transform fibroblasts even in the absence of HGF (<xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref>). In contrast, other evaluated mutations (M1149T, V1206L, L1213V, V1238I), displaying weaker activity, still required HGF stimulation for enhanced MET receptor phosphorylation and cell transformation (<xref ref-type="bibr" rid="bib17">Chiara et al., 2003</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref>). These data suggest that transformation mediated by MET mutants can depend or not on HGF, according to the initial level of kinase activation. Interestingly, mutations inducing higher MET phosphorylation (M1268T and Y1248H) occur in the C-terminal lobe of the MET receptor, specifically in or above the activation loop (<xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>), while the mutations inducing lower phosphorylation (V1206L and M1149T for instance) are located in the N-lobe or near the catalytic site of the kinase domain (between the N and C lobes). This suggests a relation between mutation location and the activation level.</p><p>With knock-in mouse models for several germline MET mutations, it has been demonstrated that these MET mutations can induce spontaneous tumorigenesis. This provides strong evidence that activating MET mutations play a key role in promoting tumorigenesis (<xref ref-type="bibr" rid="bib41">Graveel et al., 2004</xref>; <xref ref-type="bibr" rid="bib42">Graveel et al., 2005</xref>).</p><p>For most MET mutations found in renal cancers, downstream signalling pathway activation has been little or never investigated. For two kinase mutations in the C-terminal lobe, M1268T and Y1248H, an increase in endocytosis/recycling of the receptor to the membrane has been described, along with a decrease in its degradation (<xref ref-type="bibr" rid="bib55">Joffre et al., 2011</xref>).</p></sec><sec id="s5"><title>MET mutations in the juxtamembrane domain</title><p>While in renal cancers MET mutations are located exclusively in the kinase domain, in lung cancers they mainly affect the juxtamembrane domain, encoded by exon 14. The first juxtamembrane-domain-located mutations to be discovered were point mutations inducing amino acid substitutions within the domain (<xref ref-type="bibr" rid="bib108">Seiwert et al., 2009</xref>; <xref ref-type="bibr" rid="bib62">Lee et al., 2000</xref>). These mutations include R988C, P1009S, and T1010I with, for instance, about 1% of NSCLC patients harbouring R988C (<xref ref-type="bibr" rid="bib58">Krishnaswamy et al., 2009</xref>). Several studies have demonstrated that these amino acid substitutions within the juxtamembrane domain promote migration and colony formation in soft agar and increase levels of reactive oxygen species, a phenomenon liable to participate in cell transformation (<xref ref-type="bibr" rid="bib74">Ma, 2015</xref>; <xref ref-type="bibr" rid="bib48">Jagadeeswaran et al., 2007</xref>). Furthermore, it has been shown that they favour the growth of experimental tumours. Whether these mutations are really activating mutations, however, is controversial, since they do not cause MET kinase activation (<xref ref-type="bibr" rid="bib62">Lee et al., 2000</xref>; <xref ref-type="bibr" rid="bib121">Tyner et al., 2010</xref>), so their mode of action is not obvious. In addition, recent studies have shown that these mutations can be germline mutations and thus might correspond to polymorphisms ( <xref ref-type="bibr" rid="bib121">Tyner et al., 2010</xref>; <xref ref-type="bibr" rid="bib13">Boland et al., 2013</xref>). Nevertheless, strong functional evidence suggests that these mutations, even present in the germline, could favour lung cancer. In the murine strain SWRJ, the presence of the R968C MET variant, corresponding to the human R988C variant, favours the development of lung tumours upon exposure to a carcinogen (<xref ref-type="bibr" rid="bib134">Zaffaroni et al., 2005</xref>). In addition, we have recently demonstrated that the R988C mutation favours MET proteolytic cleavages by calpain, a cytoplasmic calcium-activated protease (<xref ref-type="bibr" rid="bib83">Montagne et al., 2017</xref>). This MET cleavage leads to the generation of an intracellular fragment of about 45 kDa (p45 MET), which in epithelial cells promotes migration and invasion induced by HGF stimulation. This suggests an original mechanism of MET activation, independent of activation of its kinase (<xref ref-type="bibr" rid="bib83">Montagne et al., 2017</xref>). It is worth noting that, in contrast to the p40 MET fragment generated during apoptosis (see next chapter), the p45 MET fragment is unable to amplify apoptosis. This suggests that differential MET processing by proteases generates specialized fragments according to the cell conditions (<xref ref-type="bibr" rid="bib30">Fernandes et al., 2019</xref>).</p></sec><sec id="s6"><title>MET mutations leading to exon 14 skipping</title><p>Besides mutations causing amino-acid substitutions within the juxtamembrane domain, several mutations affecting the splice junctions flanking exon 14, encoding the juxtamembrane domain, were described in 2006 in two adenocarcinoma tissues and in the NSCLC cell line H596 (<xref ref-type="bibr" rid="bib57">Kong-Beltran et al., 2006</xref>). After that, a few additional somatic alterations affecting exon 14 were described (<xref ref-type="bibr" rid="bib87">Onozato et al., 2009</xref>; <xref ref-type="bibr" rid="bib126">Vieira et al., 2014</xref>), but the rate of these mutations in lung cancers was not determined. In 2014, profiling of lung adenocarcinomas by whole-exome sequencing and mRNA sequencing revealed an approximate 3% rate of somatic mutations leading to exon 14 skipping in lung cancer (<xref ref-type="bibr" rid="bib20">Collisson et al., 2014</xref>). One year later, the great diversity of MET exon 14 alterations was proved by next-generation sequencing (NGS) across several advanced cancers, including lung, gastric, colorectal, and brain cancers (<xref ref-type="bibr" rid="bib34">Frampton et al., 2015</xref>). Since then, more than 160 different alterations affecting MET exon 14 have been described, including point mutations, deletions, insertions, and complex mutations (indels) which all affect conserved sequences of donor or acceptor splice sites (<xref ref-type="fig" rid="fig2">Figure 2A</xref>; <xref ref-type="bibr" rid="bib106">Schrock et al., 2016</xref>). At the 5’ end of the exon, most of the alterations are deletions, insertions, and indels affecting the acceptor splice site, the branch point, or the polypyrimidine tract. At the 3’ end, they are mostly point mutations affecting the donor splice site (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Interestingly, all these alterations potentially lead to in-phase exon 14 skipping, as demonstrated by RNA sequencing (<xref ref-type="bibr" rid="bib57">Kong-Beltran et al., 2006</xref>; <xref ref-type="bibr" rid="bib20">Collisson et al., 2014</xref>; <xref ref-type="bibr" rid="bib22">Davies et al., 2019</xref>). In normal mouse liver and kidney, alternative splicing affecting exon 15 (corresponding to exon 14 in human) has been described (exon 15 in transcript ID ENSMUST00000115443). It has been proved that this rare alternative splicing event induces a 141-basepair deletion predicted to result in a 47-amino-acid in-frame deletion in the juxtamembrane region of the cytoplasmic part (<xref ref-type="bibr" rid="bib61">Lee and Yamada, 1994</xref>). This rare alternative splicing event has not been described, to date, in normal human tissues, but mouse fibroblasts expressing the MET variant with the described deletion display transforming phenotypes and form tumours in immunodeficient mice. This suggests that deletion of exon 15 (corresponding to exon 14 in human) may promote tumorigenesis (<xref ref-type="bibr" rid="bib63">Lee et al., 2006</xref>; <xref ref-type="bibr" rid="bib6">Baek et al., 2004</xref>). More recently, in the exon-14-encoded juxtamembrane domain of human MET, several negative regulatory sites have been characterized. The first negative regulatory mechanism found to target the juxtamembrane region was phosphorylation of serine 1003 (Ser985 in the short MET isoform). Ser1003 is phosphorylated by protein kinase C (PKC) and dephosphorylated by protein phosphatase 2 A (PP2A) (<xref ref-type="bibr" rid="bib44">Hashigasako et al., 2004</xref>). Phosphorylation of MET Ser1003 impairs proper phosphorylation of tyrosine residues, and can thus control cell responsiveness to HGF (<xref ref-type="bibr" rid="bib36">Gandino et al., 1994</xref>). After liver injury, it has been proved that ligand-dependent activation of the MET kinase, required for tissue regeneration, correlates with decreased Ser1003 phosphorylation (<xref ref-type="bibr" rid="bib85">Nakayama et al., 2013</xref>). This suggests an involvement of Ser1003 in regulating MET activity in physiological processes. On this basis it would seem that deletion of exon 14 could confer insensitivity to MET-inhibiting signals conveyed by PKC, thus leading to MET activation.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>MET mutations leading to exon 14 skipping.</title><p>(<bold>A</bold>) Several mutations affecting the splice junctions flanking exon 14 (encoding the juxtamembrane domain) have been described in non-small cell lung cancer (NSCLC). More than 160 alterations of the exon 14 splicing sites have been described to induce exon skipping and deletion of the MET juxtamembrane domain (<xref ref-type="bibr" rid="bib119">Tovar and Graveel, 2017</xref>; <xref ref-type="bibr" rid="bib72">Ma et al., 2003</xref>; <xref ref-type="bibr" rid="bib34">Frampton et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Lee et al., 2017</xref>). (<bold>B</bold>) Under physiological conditions, MET is also phosphorylated on Tyr1021 in the justamembrane domain, which induces recruitment of Casitas B-lineage lymphoma (CBL), an E3 ubiquitin ligase involved in ubiquitination of the receptor. The ubiquitinated receptor is internalized and degraded, thereby contributing to attenuated signalling. In the absence of its ligand and in response to apoptotic stress, MET is cleaved by caspases to a fragment (p40 MET) able to amplify cell death through permeabilization of the mitochondria. Deletion of the juxtamembrane domain encoded by exon 14 can potentially lead to increased MET stability and tyrosine kinase activity and resistance to cell death. The subsequent increase in proliferation, motility, migration, invasion, and survival promotes tumorigenesis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92762-fig2-v1.tif"/></fig><p>The second identified juxtamembrane-domain residue crucial to MET downregulation is tyrosine 1021 (Tyr1003 in the short MET isoform). Following MET activation, the phosphorylated Tyr1021 residue participates in MET ubiquitination by recruiting the E3 ubiquitin ligase CBL (Casitas B-lineage lymphoma) to the DYpR motif, through interaction with the tyrosine kinase binding domain (TKB) (<xref ref-type="bibr" rid="bib92">Peschard et al., 2001</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Interestingly, the Tyr1021 mutation does not impair clathrin-dependent MET internalisation although, if the mutant is internalized, the absence of ubiquitination could prevent its efficient degradation (<xref ref-type="bibr" rid="bib66">Li et al., 2007</xref>). It has been demonstrated that MET mutated at Tyr1021 promotes more marked cell motility and displays higher stability and a greater transforming capacity than the wild-type version (<xref ref-type="bibr" rid="bib128">Weidner et al., 1995</xref>; <xref ref-type="bibr" rid="bib59">Lai et al., 2012</xref>; <xref ref-type="bibr" rid="bib1">Abella et al., 2005</xref>).</p><p>The third regulatory site on exon 14 is a caspase site involved in MET processing during apoptosis. Upon stress induction and in the absence of ligand, the MET receptor is first cleaved at a consensus caspase site in its C-terminal tail. This initial cleavage is followed by a second one, at aspartic acid 1020 (Asp1020) within an ESVD motif of the juxtamembrane domain. This leads to the generation of a 40 kDa cytoplasmic C-terminal fragment (p40 MET) containing the tyrosine kinase domain (<xref ref-type="fig" rid="fig2">Figure 2B</xref>; <xref ref-type="bibr" rid="bib33">Foveau et al., 2007</xref>; <xref ref-type="bibr" rid="bib120">Tulasne et al., 2004</xref>). During apoptosis, the level of full-length MET receptor decreases drastically after the caspase cleavages. Furthermore, the separation of the extracellular ligand-binding domain from the kinase domain prevents receptor activation by its ligand. Beside the fact that caspase cleavages inactivate the receptor, they also convert it to a pro-apoptotic fragment (p40 MET) capable of stimulating cell death, by promoting calcium flux involved in mitochondrial permeabilization (<xref ref-type="bibr" rid="bib65">Lefebvre et al., 2013</xref>). Furthermore, in knock-in mice expressing a MET variant mutated at the C-terminal caspase cleavage site, we have highlighted that production of a functional p40 MET is important for FAS-driven hepatocyte apoptosis. Thus, MET acts in vivo as a dependence receptor, through an original signalling mechanism controlling mitochondrial permeabilization (<xref ref-type="bibr" rid="bib28">Duplaquet et al., 2020</xref>). Caspase cleavages complement the different negative regulatory mechanisms that target this domain and are lost through exon 14 skipping. Interestingly, the ESVD1020 caspase cleavage site overlaps with the DYp1021R recruitment motif for CBL (ESVD1020Yp1021R), and phosphorylation of Y1021 prevents caspase cleavage. This suggests a mechanism protecting phosphorylated MET against caspase cleavage (<xref ref-type="bibr" rid="bib23">Deheuninck et al., 2009</xref>).</p><p>To study the effects of MET exon 14 skipping, investigators have used a clustered regularly interspaced short palindromic repeat (CRISPR/Cas9) system to generate the METex14Del variant in several isogenic cell models (HEK293, H292, and 16HBE cells). A tumour cell line displaying MET exon 14 skipping has also been employed. It appears, firstly, that activation of the METex14Del variant still depends on ligand stimulation. Second, METex14Del induces stronger and more sustained activation of receptor kinase activity and downstream signalling pathways, including the RAS signalling pathway, resulting in significant activation of cell responses such as migration, scattering, and invasion in vitro and metastasis in vivo (<xref ref-type="bibr" rid="bib57">Kong-Beltran et al., 2006</xref>; <xref ref-type="bibr" rid="bib31">Fernandes et al., 2023a</xref>; <xref ref-type="bibr" rid="bib117">Togashi et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Frampton et al., 2015</xref>; <xref ref-type="bibr" rid="bib71">Lu et al., 2022</xref>). Transcriptomic analyses after HGF stimulation have notably revealed expression of matrix metalloproteases known to promote motility and invasion (<xref ref-type="bibr" rid="bib14">Cabral-Pacheco et al., 2020</xref>) and to be regulated by the RAS signalling pathway (<xref ref-type="bibr" rid="bib132">Yang et al., 2014</xref>; <xref ref-type="bibr" rid="bib115">Tanimura et al., 2003</xref>; <xref ref-type="bibr" rid="bib37">Genersch et al., 2000</xref>). This suggests that sustained activation of RAS-ERK signalling by the METex14Del variant induces expression of MMPs promoting cell motility and invasion.</p><p>Only a few functional studies have explored the respective roles of the three known regulatory sites of the juxtamembrane domain in regulating receptor and downstream signalling pathway activation. It seems, however, that the CBL binding site, involved in MET ubiquitination, is a crucial regulatory site (<xref ref-type="bibr" rid="bib32">Fernandes et al., 2023b</xref>; <xref ref-type="bibr" rid="bib80">Miao and Xu, 2019</xref>). Furthermore, when METex14Del is present, other known oncogenic drivers such as KRAS (Kirsten rat sarcoma viral oncogene homolog), EGFR (epidermal growth factor receptor), and HER2 (human epidermal growth factor receptor 2) tend to be absent, which suggests that METex14Del can promote oncogenesis in the absence of other oncogenic drivers (<xref ref-type="bibr" rid="bib94">Pilotto et al., 2017</xref>). The prognostic impact of MET exon 14 skipping has not yet been studied extensively, but previously untreated patients displaying MET dysregulation in NSCLC (due to MET exon 14 skipping, MET amplification, or both) display bad prognosis (<xref ref-type="bibr" rid="bib4">Awad, 2016</xref>). These results constitute evidence that MET exon 14 skipping alterations are associated, in patients with NSCLC, with poorer outcome. This, combined with their oncogenic driver potential and their prevalence in NSCLC, makes the METex14Del variant an attractive therapeutic target.</p></sec><sec id="s7"><title>Extracellular MET mutations</title><p>Until very recently, the functional consequences of MET mutations affecting the extracellular domain were unknown. Some such mutations were viewed as polymorphisms without any functional consequences. Yet MET N375S, the most common polymorphism known to affect the MET gene and which causes an amino acid substitution in the semaphorin domain, is found also in several cancers, including lung cancers (<xref ref-type="bibr" rid="bib116">Tengs et al., 2006</xref>). Interestingly, this mutation can confer exquisite binding affinity for HER2, enabling METN375S to interact with HER2 in a ligand-independent fashion. The resulting METN375S/HER2 dimer transduces potent proliferative, pro-invasive, and pro-metastatic cues through the HER2 signaling axis to drive aggressive HNSCC and LUSC cancers (<xref ref-type="bibr" rid="bib56">Kong et al., 2020</xref>).</p></sec><sec id="s8"><title>Targeting kinase-domain MET-activating mutations with TKIs</title><p>Strategies for inhibiting MET have been developed by pharmaceutical companies and academic laboratories. One approach is to target the HGF-MET interaction with blocking antibodies. Another is to inhibit MET kinase activity with TKIs. In 2013, Choueiri et al tested, in a phase II clinical trial, the compound foretinib, an oral multikinase TKI targeting MET, VEGF, RON, AXL, and TIE-2 receptors in PRCC patients with a MET mutation. Of the patients with a germline MET mutation, five out of ten showed a positive response, while the others showed stable disease. Of the positively responding patients, four showed a 10% reduction of the tumour. Patients without a germline MET mutation showed no such response. Foretinib thus gives rise to a high response rate in patients with a germline MET mutation, with manageable toxicity similar to that of other anti-VEGFR molecules (<xref ref-type="bibr" rid="bib18">Choueiri et al., 2013</xref>).</p><p>In the SAVOIR phase III clinical trial, conducted on 60 patients with chromosomal 7 gain, MET amplification, MET kinase mutation, or HGF alteration, the effect of the MET TKI savolitinib was studied versus sunitinib. Although the study was prematurely terminated, it should be noted that savolitinib showed a response rate numerically superior to that of sunitinib: 27% vs 7%, respectively (<xref ref-type="bibr" rid="bib19">Choueiri et al., 2020</xref>). Schöffski et al., conducted a phase II clinical trial (CREATE) on type I PRCC patients with MET mutations and MET amplification to test crizotinib. Progression-free survival of more than one year was demonstrated, with durable disease control in 75% of the MET-positive patients (<xref ref-type="bibr" rid="bib105">Schöffski et al., 2017</xref>).</p><p>Finally, combination therapies have also been tested in PRCC. Combining durvalumab, a PD-L1 inhibitor, with the MET inhibitor savolitinib was studied in metastatic RCC patients. For patients with MET impairment, median progression-free survival was 12 months and overall survival was 27.4 months. Combining savolitinib and durvalumab thus seems a possibility for MET-positive tumours (<xref ref-type="bibr" rid="bib112">Suárez et al., 2023</xref>).</p><p>Several other selective and non-selective MET inhibitors are under clinical evaluation, such as INC280 in Phase II for papillary renal cell cancer, crizotinib, and cabozantinib for papillary renal cell carcinoma type 1, and nivolumab, ipilimumab, and tivantinib for papillary renal cell carcinoma type 2 (<ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/">https://www.clinicaltrials.gov/</ext-link>).</p></sec><sec id="s9"><title>Targeting METex14Del with TKIs</title><p>After initial preclinical studies demonstrating MET TKI efficacy in cell lines displaying MET exon 14 skipping mutations (<xref ref-type="bibr" rid="bib117">Togashi et al., 2015</xref>; <xref ref-type="bibr" rid="bib34">Frampton et al., 2015</xref>; <xref ref-type="bibr" rid="bib29">Engstrom et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Cecchi et al., 2016</xref>; <xref ref-type="bibr" rid="bib12">Bladt et al., 2013</xref>), several clinical trials were performed to evaluate the efficacy of MET TKIs in NSCLC patients displaying MET exon 14 skipping. First clinical evidence of MET exon 14 skipping tumours responding to a MET TKI was obtained in studies using crizotinib, an ATP-binding competitor of anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), RON, and MET (<xref ref-type="bibr" rid="bib89">Paik et al., 2015</xref>; <xref ref-type="bibr" rid="bib40">Giroux-Leprieur et al., 2016</xref>). This TKI first showed efficacy in several case studies on patients harbouring MET exon 14 skipping tumours (<xref ref-type="bibr" rid="bib89">Paik et al., 2015</xref>; <xref ref-type="bibr" rid="bib25">Drilon et al., 2016</xref>; <xref ref-type="bibr" rid="bib127">Waqar et al., 2015</xref>). Furthermore, data from a clinical trial on a relatively large cohort, in terms of the rate of MET exon 14 mutations (n=69), showed encouraging outcomes in patients with advanced NSCLC and MET exon 14 skipping, with a 9.1 month median duration of response and a 7.3 month median progression free-survival (<xref ref-type="bibr" rid="bib26">Drilon et al., 2020</xref>). On the basis of these results, in May 2018 crizotinib received breakthrough therapy designation from the United States Food and Drug Administration (US FDA), for the treatment of metastatic NSCLC in patients with MET exon 14 skipping alterations and progression on or after platinum-based chemotherapy (<xref ref-type="bibr" rid="bib25">Drilon et al., 2016</xref>; <xref ref-type="bibr" rid="bib93">Pfizer, 2020</xref>). Objective responses to other MET TKIs have likewise been observed, notably in the phase II trial VISION, in which tepotinib was found to induce an objective response in half of the MET exon 14 skipping patients, with an 11 month median duration of response and a 17.1 month median duration of overall survival (<xref ref-type="bibr" rid="bib90">Paik et al., 2020</xref>). Another MET TKI, capmatinib, gave rise to objective responses in NSCLC patients displaying a MET exon 14 mutation, including previously untreated ones (GEOMETRY trial), with a 12.6 month median response duration. These encouraging results led the Japanese Ministry of Health to approve treatment with TEPMETKO* (tepotinib) for NSCLC patients with MET exon 14 mutations (<xref ref-type="bibr" rid="bib79">Merck Global, 2020</xref>). At the same time, the US FDA granted approval of capmatinib for treating NSCLC patients harbouring MET exon14 mutations (<xref ref-type="bibr" rid="bib86">Novartis, 2020</xref>). Combined, the preclinical and clinical evidence proves that patients with MET exon 14 skipping alterations are treatable with MET TKIs, some of which are still under clinical development (<xref ref-type="bibr" rid="bib46">Hu et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Landi et al., 2019</xref>; <xref ref-type="bibr" rid="bib130">Yan et al., 2018</xref>).</p></sec><sec id="s10"><title>MET mutations involved in resistance</title><p>Over the last few years and as a consequence of the efficacy of MET TKIs in patients harbouring MET exon 14 skipping mutations, several MET TKIs (crizotinib, glesatinib, capmatinib, tepotinib) have been used in the context of clinical trials or as off-label treatments . Yet as expected for targeted therapies, after initial responses, resistances have systematically been observed. Many resistance mechanisms have been described, mostly involving activation of the usual suspects, such as other RTKs or downstream signaling hubs (<xref ref-type="bibr" rid="bib49">Jamme et al., 2020</xref>; <xref ref-type="bibr" rid="bib113">Suzawa et al., 2019</xref>). Some resistances, however, are due to on-target mutations, essentially in the MET kinase domain. In the context of this review, we can thus state that MET resists its own targeting.</p><p>The following mutated amino acids have been clinically described after treatment with a MET TKI in patients harbouring MET exon 14 skipping mutations: H1112, G1181, L1213, F1218, D1246, and Y1248, which usually emerge after only a few months of treatment with crizotinib, glesatinib, or capmatinib (<xref ref-type="fig" rid="fig3">Figure 3A and B</xref>; <xref ref-type="bibr" rid="bib5">Awad et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Dong et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Heist et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Jin et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib88">Ou et al., 2017</xref>; <xref ref-type="bibr" rid="bib98">Recondo et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">Rotow et al., 2018</xref>; <xref ref-type="bibr" rid="bib135">Zhang et al., 2017</xref>). The presence of multiple mutations in the kinase domain has also been observed (<xref ref-type="bibr" rid="bib5">Awad et al., 2018</xref>; <xref ref-type="bibr" rid="bib67">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib98">Recondo et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">Rotow et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Dong et al., 2016</xref>). For example, D1246N/H has been found with Y1248H (<xref ref-type="bibr" rid="bib24">Dong et al., 2016</xref>) and G1181R can be present with L1213V, D1246H/N, and Y1248H/S (<xref ref-type="bibr" rid="bib98">Recondo et al., 2020</xref>) in a patient’s circulating DNA.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Resistance mutations in the METex14Del variant after treatment with a MET TKI.</title><p>(<bold>A</bold>) Upon treatment of MET exon 14 skipping NSCLC patients with a type I MET TKI (able to bind the active form of MET kinase) or a type II MET TKI (able to bind the inactive form of MET kinase), secondary resistance mutations were identified. Some of them (*) were already known as activating mutations in papillary renal cancer. Note that the amino acid positions are annotated from MET transcript variant NM_000245.3 (<xref ref-type="bibr" rid="bib103">Schmidt et al., 1997</xref>; <xref ref-type="bibr" rid="bib119">Tovar and Graveel, 2017</xref>). (<bold>B</bold>) Secondary activating MET mutations were placed on the 3D structure of the MET kinase domain, along with crizotinib (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb2WGJ/pdb">https://doi.org/10.2210/pdb2WGJ/pdb</ext-link>) or merestinib (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb4EEV/pdb">https://doi.org/10.2210/pdb4EEV/pdb</ext-link>). MET mutations were inserted into the raw PDB data for MET (Research Collaboratory for Structural Bioinformatics Protein Data Bank DOI: 10.2210/pdb2WGJ/pdb and 10.2210/pdb4EEV/pdb).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-92762-fig3-v1.tif"/></fig><media mimetype="video" mime-subtype="mp4" xlink:href="elife-92762-fig3-video1.mp4" id="fig3video1"><label>Figure 3—video 1.</label><caption><title>Resistance mutations of METex14Del treated with MET TKI crizotinib.</title><p>Video of the three-dimensional crystal structure of the MET kinase domain, along with crizotinib (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb2WGJ/pdb">https://doi.org/10.2210/pdb2WGJ/pdb</ext-link>). Crizotinib (TKI type I) binds the active state (DFG sequence -in) of the kinase. MET resistance mutations were inserted into the raw PDB data for MET (Research Collaboratory for Structural Bioinformatics Protein Data Bank DOI: 10.2210/pdb2WGJ/pdb). The figures and spin structure videos were created with PyMOL software and extracted. The colour code for mutations is the same as in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p></caption></media><media mimetype="video" mime-subtype="mp4" xlink:href="elife-92762-fig3-video2.mp4" id="fig3video2"><label>Figure 3—video 2.</label><caption><title>Resistance mutations of METex14Del treated with MET TKI meristinib.</title><p>Video of the three-dimensional crystal structure of the MET kinase domain, along with merestinib (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2210/pdb4EEV/pdb">https://doi.org/10.2210/pdb4EEV/pdb</ext-link>). Merestinib (TKI type II) binds the inactive stage (DFG-out). MET resistance mutations were inserted into the raw PDB data for MET (Research Collaboratory for Structural Bioinformatics Protein Data Bank DOI: 10.2210/pdb4EEV/pdb). The figures and spin structure videos were created with PyMOL software and extracted. The colour code for mutations is the same as in <xref ref-type="fig" rid="fig3">Figure 3</xref>.</p></caption></media></fig-group><p>In the recent study of Recondo et al., among 20 patients with MET exon 14-skipping mutations who showed resistance to a MET TKI, seven (35%) displayed on-target resistances due to MET mutations, the other resistances being off-target ones (<xref ref-type="bibr" rid="bib98">Recondo et al., 2020</xref>).</p><p>Most of the MET mutations recently found associated with resistance to TKIs were already known as MET-activating mutations, notably in renal cancer (<xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>; <xref ref-type="bibr" rid="bib53">Jeffers and Vande Woude, 1999</xref>; <xref ref-type="bibr" rid="bib76">Maritano et al., 2000</xref>). Detection of these mutations in tumours suggests that they may play a direct role in resistance through ligand-independent MET activation.</p><p>Resistance to MET TKIs has also been investigated in cell models displaying MET exon 14 skipping and/or MET exon 14 skipping oncogene dependence. In Ba/F3 cells engineered to depend, for their growth, on ectopic expression of an oncogene rather than on a cytokine, 12 MET resistance mutations were revealed, including five at residues previously spotted in patients (G1181, L1213, F1218, D1246, and T1248) (<xref ref-type="bibr" rid="bib35">Fujino et al., 2019</xref>). Interestingly, mutations at positions 1246 and 1248 were involved in resistance to type I TKIs, which bind the active form of MET, while mutations at 1213 and 1218 were involved in resistance to type II TKIs, which bind the inactive form. This study thus suggests that the contribution of specific mutations to resistance may depend on the type of TKI (<xref ref-type="bibr" rid="bib35">Fujino et al., 2019</xref>). These data are also in agreement with the view that a conformational change induced by a particular mutation in the kinase domain may interfere with the binding of particular MET TKIs. For instance, the resistance mutations at positions 1181 and 1248 are consistent with steric hindrance of crizotinib binding (crizotinib being a type I TKI) (<xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="video" rid="fig3video1">Figure 3—video 1</xref>), while the resistance mutations at positions 1213 and 1218 are consistent with steric hindrance merestinib binding, the latter being a type II TKI (<xref ref-type="fig" rid="fig3">Figure 3B</xref>; <xref ref-type="video" rid="fig3video2">Figure 3—video 2</xref>). Interestingly, MET variants with resistance mutations against type I TKIs appear to be sensitive to type II inhibitors, and vice versa (<xref ref-type="bibr" rid="bib35">Fujino et al., 2019</xref>). This suggests that resistance might be overcome through the complementary activity of different MET TKIs. Similar results have been obtained on NIH3T3 cells: expression of a MET variant displaying both exon 14 skipping and a D1246N or Y1248C mutation was found to drive resistance to type I but not type II inhibitors (<xref ref-type="bibr" rid="bib29">Engstrom et al., 2017</xref>). In the same publication, the authors report a patient with a MET exon 14 skipping mutation who displayed resistance to crizotinib, associated with the presence of the following additional MET mutations: D1246N, Y1248H/S, and G1181R. On the basis of results obtained on cell models, treatment was switched from the type I inhibitor crizotinib to the type II inhibitor glesatinib. This led to the regression of some metastatic localizations, with disappearance of the Y1248H/S mutation. This disappearance was concomitant, however, with the appearance of an L1213V mutation (<xref ref-type="bibr" rid="bib29">Engstrom et al., 2017</xref>), identified in a study by <xref ref-type="bibr" rid="bib35">Fujino et al., 2019</xref> as leading to resistance to type II TKIs.</p><p>On-target resistance has also been described in the context of <italic>MET</italic> gene amplification. A case report describes a patient with an initial EGFR-activating mutation, who developed primary resistance to an EGFR TKI through <italic>MET</italic> amplification (<xref ref-type="bibr" rid="bib7">Bahcall et al., 2016</xref>). Co-treatment with an EGFR TKI and the MET TKI savolitinib led to a dramatic positive clinical response, but after several months of co-treatment, the patient experienced a relapse associated with detection of an additional MET D1246V mutation, previously described as an activating mutation (<xref ref-type="bibr" rid="bib51">Jeffers et al., 1997</xref>). In the same study, interestingly, the authors demonstrated with reconstituted MET mutations in cell lines that the D1246V mutant is resistant to type I TKIs (including savolitinib), but not to type II MET inhibitors. This finding led to adapting the treatment: the EGFR TKI was used with cabozantinib, a type II MET TKI. To this treatment, the progressive lung disease responded very well (<xref ref-type="bibr" rid="bib7">Bahcall et al., 2016</xref>). In a recent study on patients displaying MET gene amplification (following or not treatment with EGFR TKI), treatments with various TKIs led to the appearance of potential resistance mutations, including substitutions at D1246 and Y1248. Interestingly, similar mutations have been found in the context of exon 14 skipping (<xref ref-type="bibr" rid="bib133">Yao et al., 2023</xref>), suggesting that at least the main on-target resistances are common between the WT MET receptor and the METex14Del variant.</p><sec id="s10-1"><title>Conclusion</title><p>MET mutations are viewed as drivers if functional data have demonstrated their ability to induce cell transformation and/or experimental tumour growth. To date, several dozen different residues are known to be affected by amino acid substitutions leading to MET activation. Such mutations were first found in the kinase domain and recorded mainly in renal cancers. They lead to kinase domain activation and to induction of downstream intracellular pathways contributing to cell transformation. In various other cancers, other amino acid substitutions have been described within the extracellular domain and the regulatory juxtamembrane domain, but their mechanisms of action remain elusive. The vast majority of MET mutations recorded in lung cancer, in contrast to renal cancer, lead to exon 14 skipping: about 160 different mutations having been recorded (; <xref ref-type="bibr" rid="bib72">Ma et al., 2003</xref>; <xref ref-type="bibr" rid="bib106">Schrock et al., 2016</xref>; <xref ref-type="bibr" rid="bib34">Frampton et al., 2015</xref>; <xref ref-type="bibr" rid="bib64">Lee et al., 2017</xref>). Mutations leading to amino acid substitutions within the MET kinase have also been found, but to our knowledge none of them have been identified as activating mutations. Thus, although both types of mutation lead to MET receptor activation, their strict differential distribution among cancers (kinase domain for renal cancer and MET exon 14 for NSCLC) suggests that specific organ contexts favour specific transformation mechanisms. For example, it has been shown that METex14Del, in contrast to kinase-domain-mutated MET variants, induces sustained downstream signalling, including RAS-ERK signalling, well known to be activated in lung cancer. In addition, exon 14 skipping leads to loss of the caspase regulatory site and hence to resistance to apoptosis, a property that could also favour tumorigenesis in the lung. An in-depth description of the downstream signalling, transcriptional programs, and biological responses induced by MET kinase mutations and exon 14 skipping would be important in understanding the organ distribution of these MET alterations.</p><p>It is worth noting that the METex14Del variant requires HGF stimulation, in keeping with deletion of a regulatory domain (<xref ref-type="bibr" rid="bib31">Fernandes et al., 2023a</xref>). It thus seems that RTKs with activating mutations may still require ligand stimulation. Likewise, MET variants with activating mutations in the kinase domain could also require ligand stimulation to achieve full receptor activation, as suggested by numerous experimental observations demonstrating that most of the kinase-domain-mutated MET forms recorded in renal cancers can be further stimulated by HGF, with the exception of the form bearing the M1268T mutation (<xref ref-type="bibr" rid="bib17">Chiara et al., 2003</xref>; <xref ref-type="bibr" rid="bib41">Graveel et al., 2004</xref>; <xref ref-type="bibr" rid="bib81">Michieli et al., 1999</xref>; <xref ref-type="bibr" rid="bib42">Graveel et al., 2005</xref>). Consequently, HGF expression by tumour cells or by the tumour microenvironment could be an attractive biomarker for predicting MET activation and thus its sensitivity to targeted therapies, even in the context of MET mutation.</p><p>Recently, treating patients with MET TKIs has led to identifying a novel generation of MET-activating mutations able to cause resistance (<xref ref-type="bibr" rid="bib5">Awad et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Dong et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Guo et al., 2019</xref>; <xref ref-type="bibr" rid="bib45">Heist et al., 2016</xref>; <xref ref-type="bibr" rid="bib54">Jin et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Li et al., 2017</xref>; <xref ref-type="bibr" rid="bib88">Ou et al., 2017</xref>; <xref ref-type="bibr" rid="bib98">Recondo et al., 2020</xref>; <xref ref-type="bibr" rid="bib100">Rotow et al., 2018</xref>; <xref ref-type="bibr" rid="bib135">Zhang et al., 2017</xref>). These novel mutations are located mainly near the interface between MET and its TKI, easily visible in 3D structures (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), and lead to inhibition of TKI binding to its target. Interestingly, some of the resistance mutations discovered are not novel, having already been identified in hereditary and sporadic renal cancer. The fact that recent work has brought historical mutations back to the fore highlights the importance of having an exhaustive record and classification of MET mutations.</p><p>With the extensive use of high-throughput sequencing for molecular diagnosis, along with the recent use of targeted therapies against MET, novel MET mutations are thus constantly being discovered. The challenge is no longer to identify MET mutations but to characterize them functionally, in order (1) to identify them as potential targets for therapy, (2) to adapt treatment in case of resistance, (3) to understand why specific classes of mutations are associated with specific cancer types, and (4) to identify novel biomarkers in order to improve targeting of mutated MET.</p></sec></sec></body><back><sec sec-type="additional-information" id="s11"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abella</surname><given-names>JV</given-names></name><name><surname>Peschard</surname><given-names>P</given-names></name><name><surname>Naujokas</surname><given-names>MA</given-names></name><name><surname>Lin</surname><given-names>T</given-names></name><name><surname>Saucier</surname><given-names>C</given-names></name><name><surname>Urbé</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>9632</fpage><lpage>9645</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.21.9632-9645.2005</pub-id><pub-id pub-id-type="pmid">16227611</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akhtar</surname><given-names>M</given-names></name><name><surname>Al-Bozom</surname><given-names>IA</given-names></name><name><surname>Al Hussain</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Papillary renal cell carcinoma (prcc): an update</article-title><source>Advances in Anatomic Pathology</source><volume>26</volume><fpage>124</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1097/PAP.0000000000000220</pub-id><pub-id pub-id-type="pmid">30507616</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asaoka</surname><given-names>Y</given-names></name><name><surname>Tada</surname><given-names>M</given-names></name><name><surname>Ikenoue</surname><given-names>T</given-names></name><name><surname>Seto</surname><given-names>M</given-names></name><name><surname>Imai</surname><given-names>M</given-names></name><name><surname>Miyabayashi</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Kudo</surname><given-names>Y</given-names></name><name><surname>Mohri</surname><given-names>D</given-names></name><name><surname>Isomura</surname><given-names>Y</given-names></name><name><surname>Ijichi</surname><given-names>H</given-names></name><name><surname>Tateishi</surname><given-names>K</given-names></name><name><surname>Kanai</surname><given-names>F</given-names></name><name><surname>Ogawa</surname><given-names>S</given-names></name><name><surname>Omata</surname><given-names>M</given-names></name><name><surname>Koike</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Gastric cancer cell line hs746t harbors a splice site mutation of c-met causing juxtamembrane domain deletion</article-title><source>Biochemical and Biophysical Research Communications</source><volume>394</volume><fpage>1042</fpage><lpage>1046</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2010.03.120</pub-id><pub-id pub-id-type="pmid">20331976</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Impaired c-met receptor degradation mediated by met exon 14 mutations in non-small-cell lung cancer</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><fpage>879</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1200/JCO.2015.64.2777</pub-id><pub-id pub-id-type="pmid">26786927</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awad</surname><given-names>MM</given-names></name><name><surname>Bahcall</surname><given-names>M</given-names></name><name><surname>Sholl</surname><given-names>LM</given-names></name><name><surname>Wilson</surname><given-names>FH</given-names></name><name><surname>Paweletz</surname><given-names>C</given-names></name><name><surname>Capelletti</surname><given-names>M</given-names></name><name><surname>Leonardi</surname><given-names>GC</given-names></name><name><surname>Watanabe</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>H</given-names></name><name><surname>Chambers</surname><given-names>ES</given-names></name><name><surname>Redig</surname><given-names>AJ</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><name><surname>VanderLaan</surname><given-names>PA</given-names></name><name><surname>Costa</surname><given-names>DB</given-names></name><name><surname>Imamura</surname><given-names>Y</given-names></name><name><surname>Janne</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of acquired resistance to met tyrosine kinase inhibitors (tkis) in met exon 14 (metex14) mutant non-small cell lung cancer (nsclc)</article-title><source>Journal of Clinical Oncology</source><volume>36</volume><elocation-id>9069</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2018.36.15_suppl.9069</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baek</surname><given-names>CM</given-names></name><name><surname>Jeon</surname><given-names>SH</given-names></name><name><surname>Jang</surname><given-names>JJ</given-names></name><name><surname>Lee</surname><given-names>BS</given-names></name><name><surname>Lee</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Transforming variant of Met receptor confers serum independence and anti-apoptotic property and could be involved in the mouse thymic lymphomagenesis</article-title><source>Experimental &amp; Molecular Medicine</source><volume>36</volume><fpage>283</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1038/emm.2004.39</pub-id><pub-id pub-id-type="pmid">15365247</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahcall</surname><given-names>M</given-names></name><name><surname>Sim</surname><given-names>T</given-names></name><name><surname>Paweletz</surname><given-names>CP</given-names></name><name><surname>Patel</surname><given-names>JD</given-names></name><name><surname>Alden</surname><given-names>RS</given-names></name><name><surname>Kuang</surname><given-names>Y</given-names></name><name><surname>Sacher</surname><given-names>AG</given-names></name><name><surname>Kim</surname><given-names>ND</given-names></name><name><surname>Lydon</surname><given-names>CA</given-names></name><name><surname>Awad</surname><given-names>MM</given-names></name><name><surname>Jaklitsch</surname><given-names>MT</given-names></name><name><surname>Sholl</surname><given-names>LM</given-names></name><name><surname>Jänne</surname><given-names>PA</given-names></name><name><surname>Oxnard</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Acquired metd1228v mutation and resistance to met inhibition in lung cancer</article-title><source>Cancer Discovery</source><volume>6</volume><fpage>1334</fpage><lpage>1341</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-16-0686</pub-id><pub-id pub-id-type="pmid">27694386</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Longati</surname><given-names>P</given-names></name><name><surname>Gramaglia</surname><given-names>D</given-names></name><name><surname>Stella</surname><given-names>MC</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1997">1997a</year><article-title>Gab1 coupling to the HGF/Met receptor multifunctional docking site requires binding of Grb2 and correlates with the transforming potential</article-title><source>Oncogene</source><volume>15</volume><fpage>3103</fpage><lpage>3111</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201561</pub-id><pub-id pub-id-type="pmid">9444958</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Pugliese</surname><given-names>L</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1997">1997b</year><article-title>“Invasive-growth” signaling by the Met/HGF receptor: the hereditary renal carcinoma connection</article-title><source>Biochimica et Biophysica Acta</source><volume>1333</volume><fpage>M41</fpage><lpage>M51</lpage><pub-id pub-id-type="doi">10.1016/s0304-419x(97)00026-7</pub-id><pub-id pub-id-type="pmid">9426201</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Longati</surname><given-names>P</given-names></name><name><surname>Gramaglia</surname><given-names>D</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name><name><surname>Tamagnone</surname><given-names>L</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name><name><surname>Ballinari</surname><given-names>D</given-names></name><name><surname>Michieli</surname><given-names>P</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth</article-title><source>PNAS</source><volume>95</volume><fpage>14379</fpage><lpage>14383</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.24.14379</pub-id><pub-id pub-id-type="pmid">9826708</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bladt</surname><given-names>F</given-names></name><name><surname>Riethmacher</surname><given-names>D</given-names></name><name><surname>Isenmann</surname><given-names>S</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud</article-title><source>Nature</source><volume>376</volume><fpage>768</fpage><lpage>771</lpage><pub-id pub-id-type="doi">10.1038/376768a0</pub-id><pub-id pub-id-type="pmid">7651534</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bladt</surname><given-names>F</given-names></name><name><surname>Faden</surname><given-names>B</given-names></name><name><surname>Friese-Hamim</surname><given-names>M</given-names></name><name><surname>Knuehl</surname><given-names>C</given-names></name><name><surname>Wilm</surname><given-names>C</given-names></name><name><surname>Fittschen</surname><given-names>C</given-names></name><name><surname>Grädler</surname><given-names>U</given-names></name><name><surname>Meyring</surname><given-names>M</given-names></name><name><surname>Dorsch</surname><given-names>D</given-names></name><name><surname>Jaehrling</surname><given-names>F</given-names></name><name><surname>Pehl</surname><given-names>U</given-names></name><name><surname>Stieber</surname><given-names>F</given-names></name><name><surname>Schadt</surname><given-names>O</given-names></name><name><surname>Blaukat</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>2941</fpage><lpage>2951</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-3247</pub-id><pub-id pub-id-type="pmid">23553846</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boland</surname><given-names>JM</given-names></name><name><surname>Jang</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>AM</given-names></name><name><surname>Wampfler</surname><given-names>JA</given-names></name><name><surname>Erickson-Johnson</surname><given-names>MR</given-names></name><name><surname>Soares</surname><given-names>I</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Jen</surname><given-names>J</given-names></name><name><surname>Oliveira</surname><given-names>AM</given-names></name><name><surname>Yi</surname><given-names>ES</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>MET and EGFR mutations identified in ALK-rearranged pulmonary adenocarcinoma: molecular analysis of 25 ALK-positive cases</article-title><source>Journal of Thoracic Oncology</source><volume>8</volume><fpage>574</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e318287c395</pub-id><pub-id pub-id-type="pmid">23449277</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabral-Pacheco</surname><given-names>GA</given-names></name><name><surname>Garza-Veloz</surname><given-names>I</given-names></name><name><surname>Castruita-De la Rosa</surname><given-names>C</given-names></name><name><surname>Ramirez-Acuña</surname><given-names>JM</given-names></name><name><surname>Perez-Romero</surname><given-names>BA</given-names></name><name><surname>Guerrero-Rodriguez</surname><given-names>JF</given-names></name><name><surname>Martinez-Avila</surname><given-names>N</given-names></name><name><surname>Martinez-Fierro</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The roles of matrix metalloproteinases and their inhibitors in human diseases</article-title><source>International Journal of Molecular Sciences</source><volume>21</volume><elocation-id>9739</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21249739</pub-id><pub-id pub-id-type="pmid">33419373</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Cancer Genome Atlas Research Network</collab></person-group><year iso-8601-date="2023">2023</year><article-title>Comprehensive genomic characterization defines human glioblastoma genes and core494 pathways - PubMed</article-title><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18772890/">https://pubmed.ncbi.nlm.nih.gov/18772890/</ext-link><date-in-citation iso-8601-date="2023-04-24">April 24, 2023</date-in-citation></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cecchi</surname><given-names>F</given-names></name><name><surname>Rabizadeh</surname><given-names>S</given-names></name><name><surname>Weingarten</surname><given-names>P</given-names></name><name><surname>Tsai</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Hembrough</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>P-038 MET activation via exon 14 skipping mutations (METex14del): gastrointestinal prevalence and sensitivity to MET inhibitor AMG337</article-title><source>Annals of Oncology</source><volume>27</volume><elocation-id>ii11</elocation-id><pub-id pub-id-type="doi">10.1093/annonc/mdw199.36</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiara</surname><given-names>F</given-names></name><name><surname>Michieli</surname><given-names>P</given-names></name><name><surname>Pugliese</surname><given-names>L</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mutations in the met oncogene unveil a “dual switch” mechanism controlling tyrosine kinase activity</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>29352</fpage><lpage>29358</lpage><pub-id pub-id-type="doi">10.1074/jbc.M302404200</pub-id><pub-id pub-id-type="pmid">12746450</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Vaishampayan</surname><given-names>U</given-names></name><name><surname>Rosenberg</surname><given-names>JE</given-names></name><name><surname>Logan</surname><given-names>TF</given-names></name><name><surname>Harzstark</surname><given-names>AL</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Srinivas</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>MN</given-names></name><name><surname>Adams</surname><given-names>LM</given-names></name><name><surname>Ottesen</surname><given-names>LH</given-names></name><name><surname>Laubscher</surname><given-names>KH</given-names></name><name><surname>Sherman</surname><given-names>L</given-names></name><name><surname>McDermott</surname><given-names>DF</given-names></name><name><surname>Haas</surname><given-names>NB</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Ross</surname><given-names>R</given-names></name><name><surname>Eisenberg</surname><given-names>P</given-names></name><name><surname>Meltzer</surname><given-names>PS</given-names></name><name><surname>Merino</surname><given-names>MJ</given-names></name><name><surname>Bottaro</surname><given-names>DP</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Srinivasan</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma</article-title><source>Journal of Clinical Oncology</source><volume>31</volume><fpage>181</fpage><lpage>186</lpage><pub-id pub-id-type="doi">10.1200/JCO.2012.43.3383</pub-id><pub-id pub-id-type="pmid">23213094</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Heng</surname><given-names>DYC</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Cancel</surname><given-names>M</given-names></name><name><surname>Verheijen</surname><given-names>RB</given-names></name><name><surname>Mellemgaard</surname><given-names>A</given-names></name><name><surname>Ottesen</surname><given-names>LH</given-names></name><name><surname>Frigault</surname><given-names>MM</given-names></name><name><surname>L’Hernault</surname><given-names>A</given-names></name><name><surname>Szijgyarto</surname><given-names>Z</given-names></name><name><surname>Signoretti</surname><given-names>S</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Efficacy of savolitinib vs sunitinib in patients with met-driven papillary renal cell carcinoma: the savoir phase 3 randomized clinical trial</article-title><source>JAMA Oncology</source><volume>6</volume><fpage>1247</fpage><lpage>1255</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2020.2218</pub-id><pub-id pub-id-type="pmid">32469384</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collisson</surname><given-names>EA</given-names></name><name><surname>Campbell</surname><given-names>JD</given-names></name><name><surname>Brooks</surname><given-names>AN</given-names></name><name><surname>Berger</surname><given-names>AH</given-names></name><name><surname>Lee</surname><given-names>W</given-names></name><name><surname>Chmielecki</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Comprehensive molecular profiling of lung adenocarcinoma</article-title><source>Nature</source><volume>511</volume><fpage>543</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1038/nature13385</pub-id><pub-id pub-id-type="pmid">25079552</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortot</surname><given-names>AB</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name><name><surname>Descarpentries</surname><given-names>C</given-names></name><name><surname>Wislez</surname><given-names>M</given-names></name><name><surname>Baldacci</surname><given-names>S</given-names></name><name><surname>Furlan</surname><given-names>A</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Exon 14 deleted met receptor as a new biomarker and target in cancers</article-title><source>Journal of the National Cancer Institute</source><volume>109</volume><elocation-id>109</elocation-id><pub-id pub-id-type="doi">10.1093/jnci/djw262</pub-id><pub-id pub-id-type="pmid">28376232</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>KD</given-names></name><name><surname>Lomboy</surname><given-names>A</given-names></name><name><surname>Lawrence</surname><given-names>CA</given-names></name><name><surname>Yourshaw</surname><given-names>M</given-names></name><name><surname>Bocsi</surname><given-names>GT</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Aisner</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Dna-based versus rna-based detection of met exon 14 skipping events in lung cancer</article-title><source>Journal of Thoracic Oncology</source><volume>14</volume><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2018.12.020</pub-id><pub-id pub-id-type="pmid">30639620</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deheuninck</surname><given-names>J</given-names></name><name><surname>Goormachtigh</surname><given-names>G</given-names></name><name><surname>Foveau</surname><given-names>B</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Ancot</surname><given-names>F</given-names></name><name><surname>Villeret</surname><given-names>V</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name><name><surname>Fafeur</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Phosphorylation of the MET receptor on juxtamembrane tyrosine residue 1001 inhibits its caspase-dependent cleavage</article-title><source>Cellular Signalling</source><volume>21</volume><fpage>1455</fpage><lpage>1463</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2009.05.005</pub-id><pub-id pub-id-type="pmid">19450681</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>HJ</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>CL</given-names></name><name><surname>Zhou</surname><given-names>XY</given-names></name><name><surname>Lu</surname><given-names>HJ</given-names></name><name><surname>Zhou</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Response and acquired resistance to crizotinib in chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations</article-title><source>Lung Cancer</source><volume>102</volume><fpage>118</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2016.11.006</pub-id><pub-id pub-id-type="pmid">27987579</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drilon</surname><given-names>AE</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Ou</surname><given-names>SHI</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Socinski</surname><given-names>MA</given-names></name><name><surname>Weiss</surname><given-names>J</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Winter</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Monti</surname><given-names>K</given-names></name><name><surname>Wilner</surname><given-names>KD</given-names></name><name><surname>Paik</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC)</article-title><source>Journal of Clinical Oncology</source><volume>34</volume><elocation-id>108</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.108</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drilon</surname><given-names>A</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Weiss</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>SHI</given-names></name><name><surname>Camidge</surname><given-names>DR</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Otterson</surname><given-names>GA</given-names></name><name><surname>Villaruz</surname><given-names>LC</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Awad</surname><given-names>MM</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Satouchi</surname><given-names>M</given-names></name><name><surname>Hida</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Murphy</surname><given-names>DA</given-names></name><name><surname>Wang</surname><given-names>SC</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Usari</surname><given-names>T</given-names></name><name><surname>Wilner</surname><given-names>KD</given-names></name><name><surname>Paik</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration</article-title><source>Nature Medicine</source><volume>26</volume><fpage>47</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1038/s41591-019-0716-8</pub-id><pub-id pub-id-type="pmid">31932802</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duplaquet</surname><given-names>L</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name><name><surname>Baldacci</surname><given-names>S</given-names></name><name><surname>Jamme</surname><given-names>P</given-names></name><name><surname>Cortot</surname><given-names>AB</given-names></name><name><surname>Copin</surname><given-names>MC</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The multiple paths towards MET receptor addiction in cancer</article-title><source>Oncogene</source><volume>37</volume><fpage>3200</fpage><lpage>3215</lpage><pub-id pub-id-type="doi">10.1038/s41388-018-0185-4</pub-id><pub-id pub-id-type="pmid">29551767</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duplaquet</surname><given-names>L</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Vinchent</surname><given-names>A</given-names></name><name><surname>Paget</surname><given-names>S</given-names></name><name><surname>Lefebvre</surname><given-names>J</given-names></name><name><surname>Vanden Abeele</surname><given-names>F</given-names></name><name><surname>Lancel</surname><given-names>S</given-names></name><name><surname>Giffard</surname><given-names>F</given-names></name><name><surname>Paumelle</surname><given-names>R</given-names></name><name><surname>Bidaux</surname><given-names>G</given-names></name><name><surname>Heliot</surname><given-names>L</given-names></name><name><surname>Poulain</surname><given-names>L</given-names></name><name><surname>Furlan</surname><given-names>A</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Control of cell death/survival balance by the MET dependence receptor</article-title><source>eLife</source><volume>9</volume><elocation-id>e50041</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.50041</pub-id><pub-id pub-id-type="pmid">32091387</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engstrom</surname><given-names>LD</given-names></name><name><surname>Aranda</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Tovar</surname><given-names>EA</given-names></name><name><surname>Essenburg</surname><given-names>CJ</given-names></name><name><surname>Madaj</surname><given-names>Z</given-names></name><name><surname>Chiang</surname><given-names>H</given-names></name><name><surname>Briere</surname><given-names>D</given-names></name><name><surname>Hallin</surname><given-names>J</given-names></name><name><surname>Lopez-Casas</surname><given-names>PP</given-names></name><name><surname>Baños</surname><given-names>N</given-names></name><name><surname>Menendez</surname><given-names>C</given-names></name><name><surname>Hidalgo</surname><given-names>M</given-names></name><name><surname>Tassell</surname><given-names>V</given-names></name><name><surname>Chao</surname><given-names>R</given-names></name><name><surname>Chudova</surname><given-names>DI</given-names></name><name><surname>Lanman</surname><given-names>RB</given-names></name><name><surname>Olson</surname><given-names>P</given-names></name><name><surname>Bazhenova</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>SP</given-names></name><name><surname>Graveel</surname><given-names>C</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><name><surname>Shapiro</surname><given-names>GI</given-names></name><name><surname>Peled</surname><given-names>N</given-names></name><name><surname>Awad</surname><given-names>MM</given-names></name><name><surname>Jänne</surname><given-names>PA</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Glesatinib exhibits antitumor activity in lung cancer models and patients harboring <italic>MET</italic> exon 14 mutations and overcomes mutation-mediated resistance to type I MET inhibitors in nonclinical models</article-title><source>Clinical Cancer Research</source><volume>23</volume><fpage>6661</fpage><lpage>6672</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1192</pub-id><pub-id pub-id-type="pmid">28765324</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Duplaquet</surname><given-names>L</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Proteolytic cleavages of MET: the divide-and-conquer strategy of a receptor tyrosine kinase</article-title><source>BMB Reports</source><volume>52</volume><fpage>239</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.5483/BMBRep.2019.52.4.024</pub-id><pub-id pub-id-type="pmid">30670153</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Hoggard</surname><given-names>B</given-names></name><name><surname>Jamme</surname><given-names>P</given-names></name><name><surname>Paget</surname><given-names>S</given-names></name><name><surname>Truong</surname><given-names>M-J</given-names></name><name><surname>Grégoire</surname><given-names>V</given-names></name><name><surname>Vinchent</surname><given-names>A</given-names></name><name><surname>Descarpentries</surname><given-names>C</given-names></name><name><surname>Morabito</surname><given-names>A</given-names></name><name><surname>Stanislovas</surname><given-names>J</given-names></name><name><surname>Farage</surname><given-names>E</given-names></name><name><surname>Meneboo</surname><given-names>J-P</given-names></name><name><surname>Sebda</surname><given-names>S</given-names></name><name><surname>Bouchekioua-Bouzaghou</surname><given-names>K</given-names></name><name><surname>Nollet</surname><given-names>M</given-names></name><name><surname>Humez</surname><given-names>S</given-names></name><name><surname>Perera</surname><given-names>T</given-names></name><name><surname>Fromme</surname><given-names>P</given-names></name><name><surname>Grumolato</surname><given-names>L</given-names></name><name><surname>Figeac</surname><given-names>M</given-names></name><name><surname>Copin</surname><given-names>M-C</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name><name><surname>Cortot</surname><given-names>AB</given-names></name><name><surname>Kermorgant</surname><given-names>S</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023a</year><article-title>MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice</article-title><source>Molecular Oncology</source><volume>17</volume><fpage>2257</fpage><lpage>2274</lpage><pub-id pub-id-type="doi">10.1002/1878-0261.13397</pub-id><pub-id pub-id-type="pmid">36799689</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Paget</surname><given-names>S</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name><name><surname>Truong</surname><given-names>M-J</given-names></name><name><surname>Vinchent</surname><given-names>A</given-names></name><name><surname>Meneboo</surname><given-names>J-P</given-names></name><name><surname>Sebda</surname><given-names>S</given-names></name><name><surname>Werkmeister</surname><given-names>E</given-names></name><name><surname>Descarpentries</surname><given-names>C</given-names></name><name><surname>Figeac</surname><given-names>M</given-names></name><name><surname>Cortot</surname><given-names>AB</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2023">2023b</year><article-title>Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site</article-title><source>FEBS Letters</source><volume>597</volume><fpage>2301</fpage><lpage>2315</lpage><pub-id pub-id-type="doi">10.1002/1873-3468.14702</pub-id><pub-id pub-id-type="pmid">37468447</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foveau</surname><given-names>B</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Ancot</surname><given-names>F</given-names></name><name><surname>Deheuninck</surname><given-names>J</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Fafeur</surname><given-names>V</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Amplification of apoptosis through sequential caspase cleavage of the MET tyrosine kinase receptor</article-title><source>Cell Death and Differentiation</source><volume>14</volume><fpage>752</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4402080</pub-id><pub-id pub-id-type="pmid">17186028</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frampton</surname><given-names>GM</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Rosenzweig</surname><given-names>M</given-names></name><name><surname>Chmielecki</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Bauer</surname><given-names>TM</given-names></name><name><surname>Akimov</surname><given-names>M</given-names></name><name><surname>Bufill</surname><given-names>JA</given-names></name><name><surname>Lee</surname><given-names>C</given-names></name><name><surname>Jentz</surname><given-names>D</given-names></name><name><surname>Hoover</surname><given-names>R</given-names></name><name><surname>Ou</surname><given-names>S-HI</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name><name><surname>Brennan</surname><given-names>T</given-names></name><name><surname>Chalmers</surname><given-names>ZR</given-names></name><name><surname>Jaeger</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Elvin</surname><given-names>JA</given-names></name><name><surname>Erlich</surname><given-names>R</given-names></name><name><surname>Fichtenholtz</surname><given-names>A</given-names></name><name><surname>Gowen</surname><given-names>KA</given-names></name><name><surname>Greenbowe</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Khaira</surname><given-names>D</given-names></name><name><surname>McMahon</surname><given-names>C</given-names></name><name><surname>Sanford</surname><given-names>EM</given-names></name><name><surname>Roels</surname><given-names>S</given-names></name><name><surname>White</surname><given-names>J</given-names></name><name><surname>Greshock</surname><given-names>J</given-names></name><name><surname>Schlegel</surname><given-names>R</given-names></name><name><surname>Lipson</surname><given-names>D</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name><name><surname>Morosini</surname><given-names>D</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Collisson</surname><given-names>E</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Activation of met via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to met inhibitors</article-title><source>Cancer Discovery</source><volume>5</volume><fpage>850</fpage><lpage>859</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0285</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujino</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>Y</given-names></name><name><surname>Suda</surname><given-names>K</given-names></name><name><surname>Koga</surname><given-names>T</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><name><surname>Ohara</surname><given-names>S</given-names></name><name><surname>Chiba</surname><given-names>M</given-names></name><name><surname>Shimoji</surname><given-names>M</given-names></name><name><surname>Tomizawa</surname><given-names>K</given-names></name><name><surname>Takemoto</surname><given-names>T</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sensitivity and resistance of met exon 14 mutations in lung cancer to eight met tyrosine kinase inhibitors in vitro</article-title><source>Journal of Thoracic Oncology</source><volume>14</volume><fpage>1753</fpage><lpage>1765</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.06.023</pub-id><pub-id pub-id-type="pmid">31279006</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gandino</surname><given-names>L</given-names></name><name><surname>Longati</surname><given-names>P</given-names></name><name><surname>Medico</surname><given-names>E</given-names></name><name><surname>Prat</surname><given-names>M</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>1815</fpage><lpage>1820</lpage><pub-id pub-id-type="pmid">8294430</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Genersch</surname><given-names>E</given-names></name><name><surname>Hayess</surname><given-names>K</given-names></name><name><surname>Neuenfeld</surname><given-names>Y</given-names></name><name><surname>Haller</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways</article-title><source>Journal of Cell Science</source><volume>113 Pt 23</volume><fpage>4319</fpage><lpage>4330</lpage><pub-id pub-id-type="doi">10.1242/jcs.113.23.4319</pub-id><pub-id pub-id-type="pmid">11069776</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gherardi</surname><given-names>E</given-names></name><name><surname>Youles</surname><given-names>ME</given-names></name><name><surname>Miguel</surname><given-names>RN</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name><name><surname>Iamele</surname><given-names>L</given-names></name><name><surname>Gough</surname><given-names>J</given-names></name><name><surname>Bandyopadhyay</surname><given-names>A</given-names></name><name><surname>Hartmann</surname><given-names>G</given-names></name><name><surname>Butler</surname><given-names>PJG</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Functional map and domain structure of MET, the product of the c-MET protooncogene and receptor for hepatocyte growth factor/scatter factor</article-title><source>PNAS</source><volume>100</volume><fpage>12039</fpage><lpage>12044</lpage><pub-id pub-id-type="doi">10.1073/pnas.2034936100</pub-id><pub-id pub-id-type="pmid">14528000</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gherardi</surname><given-names>E</given-names></name><name><surname>Sandin</surname><given-names>S</given-names></name><name><surname>Petoukhov</surname><given-names>MV</given-names></name><name><surname>Finch</surname><given-names>J</given-names></name><name><surname>Youles</surname><given-names>ME</given-names></name><name><surname>Ofverstedt</surname><given-names>LG</given-names></name><name><surname>Miguel</surname><given-names>RN</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name><name><surname>Vande Woude</surname><given-names>GF</given-names></name><name><surname>Skoglund</surname><given-names>U</given-names></name><name><surname>Svergun</surname><given-names>DI</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Structural basis of hepatocyte growth factor/scatter factor and MET signalling</article-title><source>PNAS</source><volume>103</volume><fpage>4046</fpage><lpage>4051</lpage><pub-id pub-id-type="doi">10.1073/pnas.0509040103</pub-id><pub-id pub-id-type="pmid">16537482</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giroux-Leprieur</surname><given-names>E</given-names></name><name><surname>Fallet</surname><given-names>V</given-names></name><name><surname>Cadranel</surname><given-names>J</given-names></name><name><surname>Wislez</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Spotlight on crizotinib in the first-line treatment of ALK-positive advanced non-small-cell lung cancer: patients selection and perspectives</article-title><source>Lung Cancer</source><volume>7</volume><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.2147/LCTT.S99303</pub-id><pub-id pub-id-type="pmid">28210164</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graveel</surname><given-names>C</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Koeman</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>L-M</given-names></name><name><surname>Tessarollo</surname><given-names>L</given-names></name><name><surname>Fiscella</surname><given-names>M</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name><name><surname>Swiatek</surname><given-names>P</given-names></name><name><surname>Bronson</surname><given-names>R</given-names></name><name><surname>Vande Woude</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Activating met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele</article-title><source>PNAS</source><volume>101</volume><fpage>17198</fpage><lpage>17203</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407651101</pub-id><pub-id pub-id-type="pmid">15557554</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graveel</surname><given-names>CR</given-names></name><name><surname>London</surname><given-names>CA</given-names></name><name><surname>Vande Woude</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>A mouse model of activating Met mutations</article-title><source>Cell Cycle</source><volume>4</volume><fpage>518</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.4161/cc.4.4.1590</pub-id><pub-id pub-id-type="pmid">15738649</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>R</given-names></name><name><surname>Offin</surname><given-names>M</given-names></name><name><surname>Brannon</surname><given-names>AR</given-names></name><name><surname>Chow</surname><given-names>A</given-names></name><name><surname>Delasos</surname><given-names>L</given-names></name><name><surname>Somwar</surname><given-names>R</given-names></name><name><surname>Wilkins</surname><given-names>O</given-names></name><name><surname>Scott</surname><given-names>K</given-names></name><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Cecchi</surname><given-names>F</given-names></name><name><surname>Hembrough</surname><given-names>TA</given-names></name><name><surname>Li</surname><given-names>BT</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Arcila</surname><given-names>ME</given-names></name><name><surname>Rekhtman</surname><given-names>N</given-names></name><name><surname>Paik</surname><given-names>PK</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Zehir</surname><given-names>A</given-names></name><name><surname>Drilon</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MET inhibitor resistance in patients with MET exon 14-altered lung cancers</article-title><source>Journal of Clinical Oncology</source><volume>37</volume><elocation-id>9006</elocation-id><pub-id pub-id-type="doi">10.1200/JCO.2019.37.15_suppl.9006</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashigasako</surname><given-names>A</given-names></name><name><surname>Machide</surname><given-names>M</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Bi-directional regulation of Ser-985 phosphorylation of C-met via protein kinase C and protein phosphatase 2A involves C-Met activation and cellular responsiveness to hepatocyte growth factor</article-title><source>The Journal of Biological Chemistry</source><volume>279</volume><fpage>26445</fpage><lpage>26452</lpage><pub-id pub-id-type="doi">10.1074/jbc.M314254200</pub-id><pub-id pub-id-type="pmid">15075332</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heist</surname><given-names>RS</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name><name><surname>Borger</surname><given-names>D</given-names></name><name><surname>Gainor</surname><given-names>JF</given-names></name><name><surname>Arellano</surname><given-names>RS</given-names></name><name><surname>Le</surname><given-names>LP</given-names></name><name><surname>Dias-Santagata</surname><given-names>D</given-names></name><name><surname>Clark</surname><given-names>JW</given-names></name><name><surname>Engelman</surname><given-names>JA</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Iafrate</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Acquired resistance to crizotinib in nsclc with met exon 14 skipping</article-title><source>Journal of Thoracic Oncology</source><volume>11</volume><fpage>1242</fpage><lpage>1245</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.06.013</pub-id><pub-id pub-id-type="pmid">27343442</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Mu</surname><given-names>Q</given-names></name><name><surname>Bao</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Nam</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>B</given-names></name><name><surname>Sa</surname><given-names>JK</given-names></name><name><surname>Cho</surname><given-names>HJ</given-names></name><name><surname>Her</surname><given-names>NG</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>F</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Kang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Qian</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Nam</surname><given-names>DH</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mutational landscape of secondary glioblastoma guides met-targeted trial in brain tumor</article-title><source>Cell</source><volume>175</volume><fpage>1665</fpage><lpage>1678</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.09.038</pub-id><pub-id pub-id-type="pmid">30343896</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagadeeswaran</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>PC</given-names></name><name><surname>Seiwert</surname><given-names>TY</given-names></name><name><surname>Jagadeeswaran</surname><given-names>S</given-names></name><name><surname>Zumba</surname><given-names>O</given-names></name><name><surname>Nallasura</surname><given-names>V</given-names></name><name><surname>Ahmed</surname><given-names>S</given-names></name><name><surname>Filiberti</surname><given-names>R</given-names></name><name><surname>Paganuzzi</surname><given-names>M</given-names></name><name><surname>Puntoni</surname><given-names>R</given-names></name><name><surname>Kratzke</surname><given-names>RA</given-names></name><name><surname>Gordon</surname><given-names>GJ</given-names></name><name><surname>Sugarbaker</surname><given-names>DJ</given-names></name><name><surname>Bueno</surname><given-names>R</given-names></name><name><surname>Janamanchi</surname><given-names>V</given-names></name><name><surname>Bindokas</surname><given-names>VP</given-names></name><name><surname>Kindler</surname><given-names>HL</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma</article-title><source>Cancer Research</source><volume>66</volume><fpage>352</fpage><lpage>361</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-4567</pub-id><pub-id pub-id-type="pmid">16397249</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jagadeeswaran</surname><given-names>R</given-names></name><name><surname>Jagadeeswaran</surname><given-names>S</given-names></name><name><surname>Bindokas</surname><given-names>VP</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells</article-title><source>American Journal of Physiology. Lung Cellular and Molecular Physiology</source><volume>292</volume><fpage>L1488</fpage><lpage>L1494</lpage><pub-id pub-id-type="doi">10.1152/ajplung.00147.2006</pub-id><pub-id pub-id-type="pmid">17322284</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamme</surname><given-names>P</given-names></name><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Copin</surname><given-names>MC</given-names></name><name><surname>Descarpentries</surname><given-names>C</given-names></name><name><surname>Escande</surname><given-names>F</given-names></name><name><surname>Morabito</surname><given-names>A</given-names></name><name><surname>Grégoire</surname><given-names>V</given-names></name><name><surname>Jamme</surname><given-names>M</given-names></name><name><surname>Baldacci</surname><given-names>S</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name><name><surname>Cortot</surname><given-names>AB</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Alterations in the pi3k pathway drive resistance to met inhibitors in nsclc harboring met exon 14 skipping mutations</article-title><source>Journal of Thoracic Oncology</source><volume>15</volume><fpage>741</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2020.01.027</pub-id><pub-id pub-id-type="pmid">32169477</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jardim</surname><given-names>DLF</given-names></name><name><surname>Falchook</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Zinner</surname><given-names>R</given-names></name><name><surname>Wheler</surname><given-names>JJ</given-names></name><name><surname>Janku</surname><given-names>F</given-names></name><name><surname>Subbiah</surname><given-names>V</given-names></name><name><surname>Piha-Paul</surname><given-names>SA</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Hess</surname><given-names>K</given-names></name><name><surname>Roy-Chowdhuri</surname><given-names>S</given-names></name><name><surname>Moulder</surname><given-names>S</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Hong</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit</article-title><source>Clinical Breast Cancer</source><volume>14</volume><fpage>468</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.clbc.2014.06.001</pub-id><pub-id pub-id-type="pmid">25065564</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffers</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Nakaigawa</surname><given-names>N</given-names></name><name><surname>Webb</surname><given-names>CP</given-names></name><name><surname>Weirich</surname><given-names>G</given-names></name><name><surname>Kishida</surname><given-names>T</given-names></name><name><surname>Zbar</surname><given-names>B</given-names></name><name><surname>Vande Woude</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Activating mutations for the met tyrosine kinase receptor in human cancer</article-title><source>PNAS</source><volume>94</volume><fpage>11445</fpage><lpage>11450</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.21.11445</pub-id><pub-id pub-id-type="pmid">9326629</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffers</surname><given-names>M</given-names></name><name><surname>Fiscella</surname><given-names>M</given-names></name><name><surname>Webb</surname><given-names>CP</given-names></name><name><surname>Anver</surname><given-names>M</given-names></name><name><surname>Koochekpour</surname><given-names>S</given-names></name><name><surname>Vande Woude</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The mutationally activated Met receptor mediates motility and metastasis</article-title><source>PNAS</source><volume>95</volume><fpage>14417</fpage><lpage>14422</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.24.14417</pub-id><pub-id pub-id-type="pmid">9826715</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeffers</surname><given-names>MF</given-names></name><name><surname>Vande Woude</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Activating mutations in the Met receptor overcome the requirement for autophosphorylation of tyrosines crucial for wild type signaling</article-title><source>Oncogene</source><volume>18</volume><fpage>5120</fpage><lpage>5125</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202902</pub-id><pub-id pub-id-type="pmid">10490849</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>W</given-names></name><name><surname>Shan</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Pan</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Acquired mechanism of crizotinib resistance in nsclc with met exon 14 skipping</article-title><source>Journal of Thoracic Oncology</source><volume>14</volume><fpage>e137</fpage><lpage>e139</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2019.04.021</pub-id><pub-id pub-id-type="pmid">31055074</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joffre</surname><given-names>C</given-names></name><name><surname>Barrow</surname><given-names>R</given-names></name><name><surname>Ménard</surname><given-names>L</given-names></name><name><surname>Calleja</surname><given-names>V</given-names></name><name><surname>Hart</surname><given-names>IR</given-names></name><name><surname>Kermorgant</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A direct role for Met endocytosis in tumorigenesis</article-title><source>Nature Cell Biology</source><volume>13</volume><fpage>827</fpage><lpage>837</lpage><pub-id pub-id-type="doi">10.1038/ncb2257</pub-id><pub-id pub-id-type="pmid">21642981</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong</surname><given-names>LR</given-names></name><name><surname>Mohamed Salleh</surname><given-names>NAB</given-names></name><name><surname>Ong</surname><given-names>RW</given-names></name><name><surname>Tan</surname><given-names>TZ</given-names></name><name><surname>Syn</surname><given-names>NL</given-names></name><name><surname>Goh</surname><given-names>RM</given-names></name><name><surname>Fhu</surname><given-names>CW</given-names></name><name><surname>Tan</surname><given-names>DSW</given-names></name><name><surname>Iyer</surname><given-names>NG</given-names></name><name><surname>Kannan</surname><given-names>S</given-names></name><name><surname>Verma</surname><given-names>CS</given-names></name><name><surname>Lim</surname><given-names>YC</given-names></name><name><surname>Soo</surname><given-names>R</given-names></name><name><surname>Ho</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Lim</surname><given-names>JSJ</given-names></name><name><surname>Yan</surname><given-names>BJ</given-names></name><name><surname>Nga</surname><given-names>ME</given-names></name><name><surname>Lim</surname><given-names>SG</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name><name><surname>Lee</surname><given-names>SC</given-names></name><name><surname>Kappei</surname><given-names>D</given-names></name><name><surname>Hung</surname><given-names>HT</given-names></name><name><surname>Goh</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>1556</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-15318-5</pub-id><pub-id pub-id-type="pmid">32214092</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kong-Beltran</surname><given-names>M</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Zha</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Bhawe</surname><given-names>K</given-names></name><name><surname>Mendoza</surname><given-names>N</given-names></name><name><surname>Holcomb</surname><given-names>T</given-names></name><name><surname>Pujara</surname><given-names>K</given-names></name><name><surname>Stinson</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Severin</surname><given-names>C</given-names></name><name><surname>Rangell</surname><given-names>L</given-names></name><name><surname>Schwall</surname><given-names>R</given-names></name><name><surname>Amler</surname><given-names>L</given-names></name><name><surname>Wickramasinghe</surname><given-names>D</given-names></name><name><surname>Yauch</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Somatic mutations lead to an oncogenic deletion of met in lung cancer</article-title><source>Cancer Research</source><volume>66</volume><fpage>283</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2749</pub-id><pub-id pub-id-type="pmid">16397241</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krishnaswamy</surname><given-names>S</given-names></name><name><surname>Kanteti</surname><given-names>R</given-names></name><name><surname>Duke-Cohan</surname><given-names>JS</given-names></name><name><surname>Loganathan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>PC</given-names></name><name><surname>Sattler</surname><given-names>M</given-names></name><name><surname>Singleton</surname><given-names>PA</given-names></name><name><surname>Ramnath</surname><given-names>N</given-names></name><name><surname>Innocenti</surname><given-names>F</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name><name><surname>Ouyang</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Minna</surname><given-names>J</given-names></name><name><surname>Kozloff</surname><given-names>MF</given-names></name><name><surname>Ferguson</surname><given-names>MK</given-names></name><name><surname>Natarajan</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Garcia</surname><given-names>JGN</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Ethnic differences and functional analysis of MET mutations in lung cancer</article-title><source>Clinical Cancer Research</source><volume>15</volume><fpage>5714</fpage><lpage>5723</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0070</pub-id><pub-id pub-id-type="pmid">19723643</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>AZ</given-names></name><name><surname>Durrant</surname><given-names>M</given-names></name><name><surname>Zuo</surname><given-names>D</given-names></name><name><surname>Ratcliffe</surname><given-names>CDH</given-names></name><name><surname>Park</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>8048</fpage><lpage>8059</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.339820</pub-id><pub-id pub-id-type="pmid">22262855</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landi</surname><given-names>L</given-names></name><name><surname>Chiari</surname><given-names>R</given-names></name><name><surname>Tiseo</surname><given-names>M</given-names></name><name><surname>D’Incà</surname><given-names>F</given-names></name><name><surname>Dazzi</surname><given-names>C</given-names></name><name><surname>Chella</surname><given-names>A</given-names></name><name><surname>Delmonte</surname><given-names>A</given-names></name><name><surname>Bonanno</surname><given-names>L</given-names></name><name><surname>Giannarelli</surname><given-names>D</given-names></name><name><surname>Cortinovis</surname><given-names>DL</given-names></name><name><surname>de Marinis</surname><given-names>F</given-names></name><name><surname>Borra</surname><given-names>G</given-names></name><name><surname>Morabito</surname><given-names>A</given-names></name><name><surname>Gridelli</surname><given-names>C</given-names></name><name><surname>Galetta</surname><given-names>D</given-names></name><name><surname>Barbieri</surname><given-names>F</given-names></name><name><surname>Grossi</surname><given-names>F</given-names></name><name><surname>Capelletto</surname><given-names>E</given-names></name><name><surname>Minuti</surname><given-names>G</given-names></name><name><surname>Mazzoni</surname><given-names>F</given-names></name><name><surname>Verusio</surname><given-names>C</given-names></name><name><surname>Bria</surname><given-names>E</given-names></name><name><surname>Alì</surname><given-names>G</given-names></name><name><surname>Bruno</surname><given-names>R</given-names></name><name><surname>Proietti</surname><given-names>A</given-names></name><name><surname>Fontanini</surname><given-names>G</given-names></name><name><surname>Crinò</surname><given-names>L</given-names></name><name><surname>Cappuzzo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Crizotinib in <italic>MET</italic>-deregulated or <italic>ROS1</italic>-rearranged pretreated non-small cell lung cancer (METROS): a phase II, prospective, multicenter, two-arms trial</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>7312</fpage><lpage>7319</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0994</pub-id><pub-id pub-id-type="pmid">31416808</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Yamada</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Identification of a novel type of alternative splicing of a tyrosine kinase receptor: juxtamembrane deletion of the C-met protein kinase C serine phosphorylation regulatory site</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>19457</fpage><lpage>19461</lpage><pub-id pub-id-type="pmid">7518457</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Han</surname><given-names>SU</given-names></name><name><surname>Cho</surname><given-names>H</given-names></name><name><surname>Jennings</surname><given-names>B</given-names></name><name><surname>Gerrard</surname><given-names>B</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Zbar</surname><given-names>B</given-names></name><name><surname>Vande Woude</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>A novel germ line juxtamembrane Met mutation in human gastric cancer</article-title><source>Oncogene</source><volume>19</volume><fpage>4947</fpage><lpage>4953</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203874</pub-id><pub-id pub-id-type="pmid">11042681</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Gao</surname><given-names>CF</given-names></name><name><surname>Lee</surname><given-names>CC</given-names></name><name><surname>Kim</surname><given-names>MD</given-names></name><name><surname>Vande Woude</surname><given-names>GF</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An alternatively spliced form of Met receptor is tumorigenic</article-title><source>Experimental &amp; Molecular Medicine</source><volume>38</volume><fpage>565</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1038/emm.2006.66</pub-id><pub-id pub-id-type="pmid">17079873</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>GD</given-names></name><name><surname>Lee</surname><given-names>SE</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Yu</surname><given-names>DB</given-names></name><name><surname>Jeong</surname><given-names>HM</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Jung</surname><given-names>HS</given-names></name><name><surname>Oh</surname><given-names>E</given-names></name><name><surname>Song</surname><given-names>JY</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name><name><surname>Kim</surname><given-names>M</given-names></name><name><surname>Jung</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Shin</surname><given-names>YK</given-names></name><name><surname>Choi</surname><given-names>YL</given-names></name><name><surname>Kim</surname><given-names>HR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MET Exon 14 skipping mutations in lung adenocarcinoma: Clinicopathologic implications and prognostic values</article-title><source>Journal of Thoracic Oncology</source><volume>12</volume><fpage>1233</fpage><lpage>1246</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2017.04.031</pub-id><pub-id pub-id-type="pmid">28502721</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>J</given-names></name><name><surname>Muharram</surname><given-names>G</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name><name><surname>Montagne</surname><given-names>R</given-names></name><name><surname>Ichim</surname><given-names>G</given-names></name><name><surname>Tauszig-Delamasure</surname><given-names>S</given-names></name><name><surname>Chotteau-Lelievre</surname><given-names>A</given-names></name><name><surname>Brenner</surname><given-names>C</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Caspase-generated fragment of the Met receptor favors apoptosis via the intrinsic pathway independently of its tyrosine kinase activity</article-title><source>Cell Death &amp; Disease</source><volume>4</volume><elocation-id>e871</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.377</pub-id><pub-id pub-id-type="pmid">24136235</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Lorinczi</surname><given-names>M</given-names></name><name><surname>Ireton</surname><given-names>K</given-names></name><name><surname>Elferink</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Specific Grb2-mediated interactions regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase</article-title><source>The Journal of Biological Chemistry</source><volume>282</volume><fpage>16764</fpage><lpage>16775</lpage><pub-id pub-id-type="doi">10.1074/jbc.M610835200</pub-id><pub-id pub-id-type="pmid">17449471</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Zhang</surname><given-names>XC</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Gou</surname><given-names>LY</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Han-Zhang</surname><given-names>H</given-names></name><name><surname>Zhong</surname><given-names>WZ</given-names></name><name><surname>Chuai</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>XN</given-names></name><name><surname>Wang</surname><given-names>BC</given-names></name><name><surname>Gan</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>ZH</given-names></name><name><surname>Jiang</surname><given-names>BY</given-names></name><name><surname>Wu</surname><given-names>SP</given-names></name><name><surname>Liu</surname><given-names>SY</given-names></name><name><surname>Xu</surname><given-names>CR</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Acquired <italic>MET</italic> Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer</article-title><source>Clinical Cancer Research</source><volume>23</volume><fpage>4929</fpage><lpage>4937</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-16-3273</pub-id><pub-id pub-id-type="pmid">28396313</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Meric-Bernstam</surname><given-names>F</given-names></name><name><surname>Parinyanitikul</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Eterovic</surname><given-names>AK</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Gagea</surname><given-names>M</given-names></name><name><surname>Chavez-MacGregor</surname><given-names>M</given-names></name><name><surname>Ueno</surname><given-names>NT</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Nair</surname><given-names>L</given-names></name><name><surname>Tripathy</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>PH</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Mendelsohn</surname><given-names>J</given-names></name><name><surname>Mills</surname><given-names>GB</given-names></name><name><surname>Gonzalez-Angulo</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Functional consequence of the MET-T1010I polymorphism in breast cancer</article-title><source>Oncotarget</source><volume>6</volume><fpage>2604</fpage><lpage>2614</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.3094</pub-id><pub-id pub-id-type="pmid">25605252</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Longati</surname><given-names>P</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Ponzetto</surname><given-names>C</given-names></name><name><surname>Naldini</surname><given-names>L</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor)</article-title><source>Oncogene</source><volume>9</volume><fpage>49</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">8302603</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenzato</surname><given-names>A</given-names></name><name><surname>Olivero</surname><given-names>M</given-names></name><name><surname>Patanè</surname><given-names>S</given-names></name><name><surname>Rosso</surname><given-names>E</given-names></name><name><surname>Oliaro</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Di Renzo</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion</article-title><source>Cancer Research</source><volume>62</volume><fpage>7025</fpage><lpage>7030</lpage><pub-id pub-id-type="pmid">12460923</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Nagelberg</surname><given-names>A</given-names></name><name><surname>Chow</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Michalchuk</surname><given-names>Q</given-names></name><name><surname>Somwar</surname><given-names>R</given-names></name><name><surname>Lockwood</surname><given-names>WW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Met exon 14 splice-site mutations preferentially activate kras signaling to drive tumourigenesis</article-title><source>Cancers</source><volume>14</volume><elocation-id>1378</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14061378</pub-id><pub-id pub-id-type="pmid">35326531</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>PC</given-names></name><name><surname>Kijima</surname><given-names>T</given-names></name><name><surname>Maulik</surname><given-names>G</given-names></name><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Sattler</surname><given-names>M</given-names></name><name><surname>Griffin</surname><given-names>JD</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions</article-title><source>Cancer Research</source><volume>63</volume><fpage>6272</fpage><lpage>6281</lpage><pub-id pub-id-type="pmid">14559814</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>PC</given-names></name><name><surname>Jagadeeswaran</surname><given-names>R</given-names></name><name><surname>Jagadeesh</surname><given-names>S</given-names></name><name><surname>Tretiakova</surname><given-names>MS</given-names></name><name><surname>Nallasura</surname><given-names>V</given-names></name><name><surname>Fox</surname><given-names>EA</given-names></name><name><surname>Hansen</surname><given-names>M</given-names></name><name><surname>Schaefer</surname><given-names>E</given-names></name><name><surname>Naoki</surname><given-names>K</given-names></name><name><surname>Lader</surname><given-names>A</given-names></name><name><surname>Richards</surname><given-names>W</given-names></name><name><surname>Sugarbaker</surname><given-names>D</given-names></name><name><surname>Husain</surname><given-names>AN</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer</article-title><source>Cancer Research</source><volume>65</volume><fpage>1479</fpage><lpage>1488</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2650</pub-id><pub-id pub-id-type="pmid">15735036</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>PC</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker</article-title><source>Cancer Discovery</source><volume>5</volume><fpage>802</fpage><lpage>805</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-15-0769</pub-id><pub-id pub-id-type="pmid">26243862</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maina</surname><given-names>F</given-names></name><name><surname>Casagranda</surname><given-names>F</given-names></name><name><surname>Audero</surname><given-names>E</given-names></name><name><surname>Simeone</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Ponzetto</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Uncoupling of Grb2 from the Met receptor in vivo reveals complex roles in muscle development</article-title><source>Cell</source><volume>87</volume><fpage>531</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(00)81372-0</pub-id><pub-id pub-id-type="pmid">8898205</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maritano</surname><given-names>D</given-names></name><name><surname>Accornero</surname><given-names>P</given-names></name><name><surname>Bonifaci</surname><given-names>N</given-names></name><name><surname>Ponzetto</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Two mutations affecting conserved residues in the Met receptor operate via different mechanisms</article-title><source>Oncogene</source><volume>19</volume><fpage>1354</fpage><lpage>1361</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1203431</pub-id><pub-id pub-id-type="pmid">10713677</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Hepatocyte growth factor: molecular structure, roles in liver regeneration, and other biological functions</article-title><source>Critical Reviews in Oncogenesis</source><volume>3</volume><fpage>27</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">1312869</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendhiratta</surname><given-names>N</given-names></name><name><surname>Muraki</surname><given-names>P</given-names></name><name><surname>Sisk</surname><given-names>AE</given-names></name><name><surname>Shuch</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Papillary renal cell carcinoma: review</article-title><source>Urologic Oncology</source><volume>39</volume><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1016/j.urolonc.2021.04.013</pub-id><pub-id pub-id-type="pmid">34034966</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Merck Global</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Tepotinib - News - Merck Global</article-title><ext-link ext-link-type="uri" xlink:href="https://www.merckgroup.com/en/news/tepotinib-25-03-2020.html">https://www.merckgroup.com/en/news/tepotinib-25-03-2020.html</ext-link><date-in-citation iso-8601-date="2020-06-14">June 14, 2020</date-in-citation></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>YL</given-names></name><name><surname>Xu</surname><given-names>QQ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma</article-title><source>Lung Cancer</source><volume>130</volume><fpage>84</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2019.02.002</pub-id><pub-id pub-id-type="pmid">30885356</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michieli</surname><given-names>P</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name><name><surname>Pennacchietti</surname><given-names>S</given-names></name><name><surname>Maffè</surname><given-names>A</given-names></name><name><surname>Tamagnone</surname><given-names>L</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists</article-title><source>Oncogene</source><volume>18</volume><fpage>5221</fpage><lpage>5231</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202899</pub-id><pub-id pub-id-type="pmid">10498872</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagne</surname><given-names>R</given-names></name><name><surname>Furlan</surname><given-names>A</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Le récepteur Met fête ses 30 ans</article-title><source>Médecine/Sciences</source><volume>30</volume><fpage>864</fpage><lpage>873</lpage><pub-id pub-id-type="doi">10.1051/medsci/20143010013</pub-id><pub-id pub-id-type="pmid">25311021</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montagne</surname><given-names>R</given-names></name><name><surname>Baranzelli</surname><given-names>A</given-names></name><name><surname>Muharram</surname><given-names>G</given-names></name><name><surname>Catherine</surname><given-names>L</given-names></name><name><surname>Lesaffre</surname><given-names>M</given-names></name><name><surname>Vinchent</surname><given-names>A</given-names></name><name><surname>Kherrouche</surname><given-names>Z</given-names></name><name><surname>Werkmeister</surname><given-names>E</given-names></name><name><surname>Cortot</surname><given-names>AB</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering</article-title><source>Oncotarget</source><volume>8</volume><fpage>11268</fpage><lpage>11283</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.14499</pub-id><pub-id pub-id-type="pmid">28061464</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>YW</given-names></name><name><surname>Weil</surname><given-names>RJ</given-names></name><name><surname>Pack</surname><given-names>SD</given-names></name><name><surname>Park</surname><given-names>WS</given-names></name><name><surname>Pak</surname><given-names>E</given-names></name><name><surname>Pham</surname><given-names>T</given-names></name><name><surname>Karkera</surname><given-names>JD</given-names></name><name><surname>Kim</surname><given-names>HK</given-names></name><name><surname>Vortmeyer</surname><given-names>AO</given-names></name><name><surname>Fuller</surname><given-names>BG</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Missense mutation of the MET gene detected in human glioma</article-title><source>Modern Pathology</source><volume>13</volume><fpage>973</fpage><lpage>977</lpage><pub-id pub-id-type="doi">10.1038/modpathol.3880177</pub-id><pub-id pub-id-type="pmid">11007037</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakayama</surname><given-names>M</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>A</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Met/HGF receptor activation is regulated by juxtamembrane Ser985 phosphorylation in hepatocytes</article-title><source>Cytokine</source><volume>62</volume><fpage>446</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.1016/j.cyto.2013.04.006</pub-id><pub-id pub-id-type="pmid">23618918</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Novartis</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials</article-title><ext-link ext-link-type="uri" xlink:href="https://www.novartis.com/news/media-releases/novartis-shows-growing-strength-lung-cancer-innovation-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials">https://www.novartis.com/news/media-releases/novartis-shows-growing-strength-lung-cancer-innovation-new-capmatinib-investigational-data-and-novel-canakinumab-clinical-trials</ext-link><date-in-citation iso-8601-date="2020-06-08">June 8, 2020</date-in-citation></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onozato</surname><given-names>R</given-names></name><name><surname>Kosaka</surname><given-names>T</given-names></name><name><surname>Kuwano</surname><given-names>H</given-names></name><name><surname>Sekido</surname><given-names>Y</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers</article-title><source>Journal of Thoracic Oncology</source><volume>4</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1097/JTO.0b013e3181913e0e</pub-id><pub-id pub-id-type="pmid">19096300</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ou</surname><given-names>SHI</given-names></name><name><surname>Young</surname><given-names>L</given-names></name><name><surname>Schrock</surname><given-names>AB</given-names></name><name><surname>Johnson</surname><given-names>A</given-names></name><name><surname>Klempner</surname><given-names>SJ</given-names></name><name><surname>Zhu</surname><given-names>VW</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Emergence of preexisting met y1230c mutation as a resistance mechanism to crizotinib in nsclc with met exon 14 skipping</article-title><source>Journal of Thoracic Oncology</source><volume>12</volume><fpage>137</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.09.119</pub-id><pub-id pub-id-type="pmid">27666659</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>PK</given-names></name><name><surname>Drilon</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>PD</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Rekhtman</surname><given-names>N</given-names></name><name><surname>Ginsberg</surname><given-names>MS</given-names></name><name><surname>Borsu</surname><given-names>L</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name><name><surname>Berger</surname><given-names>MF</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping</article-title><source>Cancer Discovery</source><volume>5</volume><fpage>842</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-1467</pub-id><pub-id pub-id-type="pmid">25971939</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paik</surname><given-names>PK</given-names></name><name><surname>Felip</surname><given-names>E</given-names></name><name><surname>Veillon</surname><given-names>R</given-names></name><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Cortot</surname><given-names>AB</given-names></name><name><surname>Garassino</surname><given-names>MC</given-names></name><name><surname>Mazieres</surname><given-names>J</given-names></name><name><surname>Viteri</surname><given-names>S</given-names></name><name><surname>Senellart</surname><given-names>H</given-names></name><name><surname>Van Meerbeeck</surname><given-names>J</given-names></name><name><surname>Raskin</surname><given-names>J</given-names></name><name><surname>Reinmuth</surname><given-names>N</given-names></name><name><surname>Conte</surname><given-names>P</given-names></name><name><surname>Kowalski</surname><given-names>D</given-names></name><name><surname>Cho</surname><given-names>BC</given-names></name><name><surname>Patel</surname><given-names>JD</given-names></name><name><surname>Horn</surname><given-names>L</given-names></name><name><surname>Griesinger</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>YC</given-names></name><name><surname>Chang</surname><given-names>GC</given-names></name><name><surname>Tsai</surname><given-names>CL</given-names></name><name><surname>Yang</surname><given-names>JCH</given-names></name><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Smit</surname><given-names>EF</given-names></name><name><surname>van der Wekken</surname><given-names>AJ</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Juraeva</surname><given-names>D</given-names></name><name><surname>Stroh</surname><given-names>C</given-names></name><name><surname>Bruns</surname><given-names>R</given-names></name><name><surname>Straub</surname><given-names>J</given-names></name><name><surname>Johne</surname><given-names>A</given-names></name><name><surname>Scheele</surname><given-names>J</given-names></name><name><surname>Heymach</surname><given-names>JV</given-names></name><name><surname>Le</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Tepotinib in non-small-cell lung cancer with <italic>MET</italic> Exon 14 skipping mutations</article-title><source>The New England Journal of Medicine</source><volume>383</volume><fpage>931</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa2004407</pub-id><pub-id pub-id-type="pmid">32469185</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>WS</given-names></name><name><surname>Dong</surname><given-names>SM</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Na</surname><given-names>EY</given-names></name><name><surname>Shin</surname><given-names>MS</given-names></name><name><surname>Pi</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Bae</surname><given-names>JH</given-names></name><name><surname>Hong</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>KS</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Yoo</surname><given-names>NJ</given-names></name><name><surname>Jang</surname><given-names>JJ</given-names></name><name><surname>Pack</surname><given-names>S</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Zbar</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas</article-title><source>Cancer Research</source><volume>59</volume><fpage>307</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">9927037</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschard</surname><given-names>P</given-names></name><name><surname>Fournier</surname><given-names>TM</given-names></name><name><surname>Lamorte</surname><given-names>L</given-names></name><name><surname>Naujokas</surname><given-names>MA</given-names></name><name><surname>Band</surname><given-names>H</given-names></name><name><surname>Langdon</surname><given-names>WY</given-names></name><name><surname>Park</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein</article-title><source>Molecular Cell</source><volume>8</volume><fpage>995</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(01)00378-1</pub-id><pub-id pub-id-type="pmid">11741535</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Pfizer</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Pfizer’s XALKORI (crizotinib) Receives FDA Breakthrough Therapy Designation in Two New Indications</article-title><ext-link ext-link-type="uri" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0">https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_xalkori_crizotinib_receives_fda_breakthrough_therapy_designation_in_two_new_indications-0</ext-link><date-in-citation iso-8601-date="2020-06-08">June 8, 2020</date-in-citation></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pilotto</surname><given-names>S</given-names></name><name><surname>Gkountakos</surname><given-names>A</given-names></name><name><surname>Carbognin</surname><given-names>L</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Tortora</surname><given-names>G</given-names></name><name><surname>Bria</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy</article-title><source>Annals of Translational Medicine</source><volume>5</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.21037/atm.2016.12.33</pub-id><pub-id pub-id-type="pmid">28164087</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponzetto</surname><given-names>C</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name><name><surname>Peverali</surname><given-names>F</given-names></name><name><surname>Della Valle</surname><given-names>G</given-names></name><name><surname>Abate</surname><given-names>ML</given-names></name><name><surname>Vaula</surname><given-names>G</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>c-met is amplified but not mutated in a cell line with an activated met tyrosine kinase</article-title><source>Oncogene</source><volume>6</volume><fpage>553</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">1674365</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponzetto</surname><given-names>C</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Maina</surname><given-names>F</given-names></name><name><surname>Longati</surname><given-names>P</given-names></name><name><surname>Panayotou</surname><given-names>G</given-names></name><name><surname>Dhand</surname><given-names>R</given-names></name><name><surname>Waterfield</surname><given-names>MD</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>A novel recognition motif for phosphatidylinositol 3-kinase binding mediates its association with the hepatocyte growth factor/scatter factor receptor</article-title><source>Molecular and Cellular Biology</source><volume>13</volume><fpage>4600</fpage><lpage>4608</lpage><pub-id pub-id-type="doi">10.1128/mcb.13.8.4600-4608.1993</pub-id><pub-id pub-id-type="pmid">7687741</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponzetto</surname><given-names>C</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Zhen</surname><given-names>Z</given-names></name><name><surname>Maina</surname><given-names>F</given-names></name><name><surname>dalla Zonca</surname><given-names>P</given-names></name><name><surname>Giordano</surname><given-names>S</given-names></name><name><surname>Graziani</surname><given-names>A</given-names></name><name><surname>Panayotou</surname><given-names>G</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family</article-title><source>Cell</source><volume>77</volume><fpage>261</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(94)90318-2</pub-id><pub-id pub-id-type="pmid">7513258</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Recondo</surname><given-names>G</given-names></name><name><surname>Bahcall</surname><given-names>M</given-names></name><name><surname>Spurr</surname><given-names>LF</given-names></name><name><surname>Che</surname><given-names>J</given-names></name><name><surname>Ricciuti</surname><given-names>B</given-names></name><name><surname>Leonardi</surname><given-names>GC</given-names></name><name><surname>Lo</surname><given-names>YC</given-names></name><name><surname>Li</surname><given-names>YY</given-names></name><name><surname>Lamberti</surname><given-names>G</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Milan</surname><given-names>MSD</given-names></name><name><surname>Venkatraman</surname><given-names>D</given-names></name><name><surname>Umeton</surname><given-names>R</given-names></name><name><surname>Paweletz</surname><given-names>CP</given-names></name><name><surname>Albayrak</surname><given-names>A</given-names></name><name><surname>Cherniack</surname><given-names>AD</given-names></name><name><surname>Price</surname><given-names>KS</given-names></name><name><surname>Fairclough</surname><given-names>SR</given-names></name><name><surname>Nishino</surname><given-names>M</given-names></name><name><surname>Sholl</surname><given-names>LM</given-names></name><name><surname>Oxnard</surname><given-names>GR</given-names></name><name><surname>Jänne</surname><given-names>PA</given-names></name><name><surname>Awad</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular mechanisms of acquired resistance to met tyrosine kinase inhibitors in patients with met exon 14-mutant nsclc</article-title><source>Clinical Cancer Research</source><volume>26</volume><fpage>2615</fpage><lpage>2625</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-3608</pub-id><pub-id pub-id-type="pmid">32034073</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhoades Smith</surname><given-names>KE</given-names></name><name><surname>Bilen</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A review of papillary renal cell carcinoma and met inhibitors</article-title><source>Kidney Cancer</source><volume>3</volume><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.3233/KCA-190058</pub-id><pub-id pub-id-type="pmid">31867475</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Rotow</surname><given-names>JK</given-names></name><name><surname>Gui</surname><given-names>P</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Raymond</surname><given-names>VM</given-names></name><name><surname>Lanman</surname><given-names>RB</given-names></name><name><surname>Kaye</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Co-occurring genetic alterations in the ras pathway promote resistance to met inhibitor treatment in non-small cell lung cancer with a met exon 14 skipping mutation</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/374181</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubin</surname><given-names>JS</given-names></name><name><surname>Bottaro</surname><given-names>DP</given-names></name><name><surname>Aaronson</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product</article-title><source>Biochimica et Biophysica Acta</source><volume>1155</volume><fpage>357</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1016/0304-419x(93)90015-5</pub-id><pub-id pub-id-type="pmid">8268192</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>C</given-names></name><name><surname>Bladt</surname><given-names>F</given-names></name><name><surname>Goedecke</surname><given-names>S</given-names></name><name><surname>Brinkmann</surname><given-names>V</given-names></name><name><surname>Zschiesche</surname><given-names>W</given-names></name><name><surname>Sharpe</surname><given-names>M</given-names></name><name><surname>Gherardi</surname><given-names>E</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Scatter factor/hepatocyte growth factor is essential for liver development</article-title><source>Nature</source><volume>373</volume><fpage>699</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1038/373699a0</pub-id><pub-id pub-id-type="pmid">7854452</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Duh</surname><given-names>FM</given-names></name><name><surname>Chen</surname><given-names>F</given-names></name><name><surname>Kishida</surname><given-names>T</given-names></name><name><surname>Glenn</surname><given-names>G</given-names></name><name><surname>Choyke</surname><given-names>P</given-names></name><name><surname>Scherer</surname><given-names>SW</given-names></name><name><surname>Zhuang</surname><given-names>Z</given-names></name><name><surname>Lubensky</surname><given-names>I</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Allikmets</surname><given-names>R</given-names></name><name><surname>Chidambaram</surname><given-names>A</given-names></name><name><surname>Bergerheim</surname><given-names>UR</given-names></name><name><surname>Feltis</surname><given-names>JT</given-names></name><name><surname>Casadevall</surname><given-names>C</given-names></name><name><surname>Zamarron</surname><given-names>A</given-names></name><name><surname>Bernues</surname><given-names>M</given-names></name><name><surname>Richard</surname><given-names>S</given-names></name><name><surname>Lips</surname><given-names>CJ</given-names></name><name><surname>Walther</surname><given-names>MM</given-names></name><name><surname>Tsui</surname><given-names>LC</given-names></name><name><surname>Geil</surname><given-names>L</given-names></name><name><surname>Orcutt</surname><given-names>ML</given-names></name><name><surname>Stackhouse</surname><given-names>T</given-names></name><name><surname>Lipan</surname><given-names>J</given-names></name><name><surname>Slife</surname><given-names>L</given-names></name><name><surname>Brauch</surname><given-names>H</given-names></name><name><surname>Decker</surname><given-names>J</given-names></name><name><surname>Niehans</surname><given-names>G</given-names></name><name><surname>Hughson</surname><given-names>MD</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Storkel</surname><given-names>S</given-names></name><name><surname>Lerman</surname><given-names>MI</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Zbar</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas</article-title><source>Nature Genetics</source><volume>16</volume><fpage>68</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/ng0597-68</pub-id><pub-id pub-id-type="pmid">9140397</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>L</given-names></name><name><surname>Junker</surname><given-names>K</given-names></name><name><surname>Nakaigawa</surname><given-names>N</given-names></name><name><surname>Kinjerski</surname><given-names>T</given-names></name><name><surname>Weirich</surname><given-names>G</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Lubensky</surname><given-names>I</given-names></name><name><surname>Neumann</surname><given-names>HP</given-names></name><name><surname>Brauch</surname><given-names>H</given-names></name><name><surname>Decker</surname><given-names>J</given-names></name><name><surname>Vocke</surname><given-names>C</given-names></name><name><surname>Brown</surname><given-names>JA</given-names></name><name><surname>Jenkins</surname><given-names>R</given-names></name><name><surname>Richard</surname><given-names>S</given-names></name><name><surname>Bergerheim</surname><given-names>U</given-names></name><name><surname>Gerrard</surname><given-names>B</given-names></name><name><surname>Dean</surname><given-names>M</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name><name><surname>Zbar</surname><given-names>B</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Novel mutations of the MET proto-oncogene in papillary renal carcinomas</article-title><source>Oncogene</source><volume>18</volume><fpage>2343</fpage><lpage>2350</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202547</pub-id><pub-id pub-id-type="pmid">10327054</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schöffski</surname><given-names>P</given-names></name><name><surname>Wozniak</surname><given-names>A</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Rutkowski</surname><given-names>P</given-names></name><name><surname>Anthoney</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>S</given-names></name><name><surname>Sufliarsky</surname><given-names>J</given-names></name><name><surname>van Herpen</surname><given-names>C</given-names></name><name><surname>Lindner</surname><given-names>LH</given-names></name><name><surname>Grünwald</surname><given-names>V</given-names></name><name><surname>Zakotnik</surname><given-names>B</given-names></name><name><surname>Lerut</surname><given-names>E</given-names></name><name><surname>Debiec-Rychter</surname><given-names>M</given-names></name><name><surname>Marréaud</surname><given-names>S</given-names></name><name><surname>Lia</surname><given-names>M</given-names></name><name><surname>Raveloarivahy</surname><given-names>T</given-names></name><name><surname>Collette</surname><given-names>S</given-names></name><name><surname>Albiges</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification: EORTC 90101 CREATE trial</article-title><source>European Journal of Cancer</source><volume>87</volume><fpage>147</fpage><lpage>163</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2017.10.014</pub-id><pub-id pub-id-type="pmid">29149761</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrock</surname><given-names>AB</given-names></name><name><surname>Frampton</surname><given-names>GM</given-names></name><name><surname>Suh</surname><given-names>J</given-names></name><name><surname>Chalmers</surname><given-names>ZR</given-names></name><name><surname>Rosenzweig</surname><given-names>M</given-names></name><name><surname>Erlich</surname><given-names>RL</given-names></name><name><surname>Halmos</surname><given-names>B</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Forde</surname><given-names>P</given-names></name><name><surname>Leuenberger</surname><given-names>K</given-names></name><name><surname>Peled</surname><given-names>N</given-names></name><name><surname>Kalemkerian</surname><given-names>GP</given-names></name><name><surname>Ross</surname><given-names>JS</given-names></name><name><surname>Stephens</surname><given-names>PJ</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Ali</surname><given-names>SM</given-names></name><name><surname>Ou</surname><given-names>SHI</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Characterization of 298 patients with lung cancer harboring met exon 14 skipping alterations</article-title><source>Journal of Thoracic Oncology</source><volume>11</volume><fpage>1493</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1016/j.jtho.2016.06.004</pub-id><pub-id pub-id-type="pmid">27343443</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sebai</surname><given-names>M</given-names></name><name><surname>Tulasne</surname><given-names>D</given-names></name><name><surname>Caputo</surname><given-names>SM</given-names></name><name><surname>Verkarre</surname><given-names>V</given-names></name><name><surname>Fernandes</surname><given-names>M</given-names></name><name><surname>Guérin</surname><given-names>C</given-names></name><name><surname>Reinhart</surname><given-names>F</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Maugard</surname><given-names>C</given-names></name><name><surname>Caron</surname><given-names>O</given-names></name><name><surname>Guillaud-Bataille</surname><given-names>M</given-names></name><name><surname>Berthet</surname><given-names>P</given-names></name><name><surname>Bignon</surname><given-names>YJ</given-names></name><name><surname>Bressac-de Paillerets</surname><given-names>B</given-names></name><name><surname>Burnichon</surname><given-names>N</given-names></name><name><surname>Chiesa</surname><given-names>J</given-names></name><name><surname>Giraud</surname><given-names>S</given-names></name><name><surname>Lejeune</surname><given-names>S</given-names></name><name><surname>Limacher</surname><given-names>JM</given-names></name><name><surname>de Pauw</surname><given-names>A</given-names></name><name><surname>Stoppa-Lyonnet</surname><given-names>D</given-names></name><name><surname>Zattara-Cannoni</surname><given-names>H</given-names></name><name><surname>Deveaux</surname><given-names>S</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><name><surname>Richard</surname><given-names>S</given-names></name><name><surname>Rouleau</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I</article-title><source>Human Mutation</source><volume>43</volume><fpage>316</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1002/humu.24313</pub-id><pub-id pub-id-type="pmid">34882875</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seiwert</surname><given-names>TY</given-names></name><name><surname>Jagadeeswaran</surname><given-names>R</given-names></name><name><surname>Faoro</surname><given-names>L</given-names></name><name><surname>Janamanchi</surname><given-names>V</given-names></name><name><surname>Nallasura</surname><given-names>V</given-names></name><name><surname>El Dinali</surname><given-names>M</given-names></name><name><surname>Yala</surname><given-names>S</given-names></name><name><surname>Kanteti</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>EEW</given-names></name><name><surname>Lingen</surname><given-names>MW</given-names></name><name><surname>Martin</surname><given-names>L</given-names></name><name><surname>Krishnaswamy</surname><given-names>S</given-names></name><name><surname>Klein-Szanto</surname><given-names>A</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Vokes</surname><given-names>EE</given-names></name><name><surname>Salgia</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma</article-title><source>Cancer Research</source><volume>69</volume><fpage>3021</fpage><lpage>3031</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2881</pub-id><pub-id pub-id-type="pmid">19318576</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stella</surname><given-names>MC</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>HGF: A multifunctional growth factor controlling cell scattering</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>31</volume><fpage>1357</fpage><lpage>1362</lpage><pub-id pub-id-type="doi">10.1016/s1357-2725(99)00089-8</pub-id><pub-id pub-id-type="pmid">10641789</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stella</surname><given-names>GM</given-names></name><name><surname>Benvenuti</surname><given-names>S</given-names></name><name><surname>Gramaglia</surname><given-names>D</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Tomezzoli</surname><given-names>A</given-names></name><name><surname>Cassoni</surname><given-names>P</given-names></name><name><surname>Senetta</surname><given-names>R</given-names></name><name><surname>Venesio</surname><given-names>T</given-names></name><name><surname>Pozzi</surname><given-names>E</given-names></name><name><surname>Bardelli</surname><given-names>A</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>MET mutations in cancers of unknown primary origin (CUPs)</article-title><source>Human Mutation</source><volume>32</volume><fpage>44</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1002/humu.21374</pub-id><pub-id pub-id-type="pmid">20949619</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stransky</surname><given-names>N</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Schalm</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JL</given-names></name><name><surname>Lengauer</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The landscape of kinase fusions in cancer</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>4846</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms5846</pub-id><pub-id pub-id-type="pmid">25204415</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suárez</surname><given-names>C</given-names></name><name><surname>Larkin</surname><given-names>JMG</given-names></name><name><surname>Patel</surname><given-names>P</given-names></name><name><surname>Valderrama</surname><given-names>BP</given-names></name><name><surname>Rodriguez-Vida</surname><given-names>A</given-names></name><name><surname>Glen</surname><given-names>H</given-names></name><name><surname>Thistlethwaite</surname><given-names>F</given-names></name><name><surname>Ralph</surname><given-names>C</given-names></name><name><surname>Srinivasan</surname><given-names>G</given-names></name><name><surname>Mendez-Vidal</surname><given-names>MJ</given-names></name><name><surname>Hartmaier</surname><given-names>R</given-names></name><name><surname>Markovets</surname><given-names>A</given-names></name><name><surname>Prendergast</surname><given-names>A</given-names></name><name><surname>Szabados</surname><given-names>B</given-names></name><name><surname>Mousa</surname><given-names>K</given-names></name><name><surname>Powles</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Phase ii study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (calypso)</article-title><source>Journal of Clinical Oncology</source><volume>41</volume><fpage>2493</fpage><lpage>2502</lpage><pub-id pub-id-type="doi">10.1200/JCO.22.01414</pub-id><pub-id pub-id-type="pmid">36809050</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suzawa</surname><given-names>K</given-names></name><name><surname>Offin</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>D</given-names></name><name><surname>Kurzatkowski</surname><given-names>C</given-names></name><name><surname>Vojnic</surname><given-names>M</given-names></name><name><surname>Smith</surname><given-names>RS</given-names></name><name><surname>Sabari</surname><given-names>JK</given-names></name><name><surname>Tai</surname><given-names>H</given-names></name><name><surname>Mattar</surname><given-names>M</given-names></name><name><surname>Khodos</surname><given-names>I</given-names></name><name><surname>de Stanchina</surname><given-names>E</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Arcila</surname><given-names>ME</given-names></name><name><surname>Lockwood</surname><given-names>WW</given-names></name><name><surname>Drilon</surname><given-names>A</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Somwar</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Activation of kras mediates resistance to targeted therapy in met exon 14–mutant non–small cell lung cancer</article-title><source>Clinical Cancer Research</source><volume>25</volume><fpage>1248</fpage><lpage>1260</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1640</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamagnone</surname><given-names>L</given-names></name><name><surname>Comoglio</surname><given-names>PM</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Control of invasive growth by hepatocyte growth factor (HGF) and related scatter factors</article-title><source>Cytokine &amp; Growth Factor Reviews</source><volume>8</volume><fpage>129</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/s1359-6101(97)00007-5</pub-id><pub-id pub-id-type="pmid">9244408</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanimura</surname><given-names>S</given-names></name><name><surname>Asato</surname><given-names>K</given-names></name><name><surname>Fujishiro</surname><given-names>S</given-names></name><name><surname>Kohno</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: down-regulation of matrix metalloproteinase-3/-9/-14 and CD44</article-title><source>Biochemical and Biophysical Research Communications</source><volume>304</volume><fpage>801</fpage><lpage>806</lpage><pub-id pub-id-type="doi">10.1016/s0006-291x(03)00670-3</pub-id><pub-id pub-id-type="pmid">12727228</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tengs</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Paez</surname><given-names>JG</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>LaFramboise</surname><given-names>T</given-names></name><name><surname>Giannoukos</surname><given-names>G</given-names></name><name><surname>Thomas</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing</article-title><source>Cancer Letters</source><volume>239</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2005.08.007</pub-id><pub-id pub-id-type="pmid">16171945</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Togashi</surname><given-names>Y</given-names></name><name><surname>Mizuuchi</surname><given-names>H</given-names></name><name><surname>Tomida</surname><given-names>S</given-names></name><name><surname>Terashima</surname><given-names>M</given-names></name><name><surname>Hayashi</surname><given-names>H</given-names></name><name><surname>Nishio</surname><given-names>K</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor</article-title><source>Lung Cancer</source><volume>90</volume><fpage>590</fpage><lpage>597</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2015.10.020</pub-id><pub-id pub-id-type="pmid">26547802</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tong</surname><given-names>CYK</given-names></name><name><surname>Hui</surname><given-names>ABY</given-names></name><name><surname>Yin</surname><given-names>XL</given-names></name><name><surname>Pang</surname><given-names>JCS</given-names></name><name><surname>Zhu</surname><given-names>XL</given-names></name><name><surname>Poon</surname><given-names>WS</given-names></name><name><surname>Ng</surname><given-names>HK</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization</article-title><source>Journal of Neurosurgery</source><volume>100</volume><fpage>187</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.3171/ped.2004.100.2.0187</pub-id><pub-id pub-id-type="pmid">14758948</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tovar</surname><given-names>EA</given-names></name><name><surname>Graveel</surname><given-names>CR</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>MET in human cancer: germline and somatic mutations</article-title><source>Annals of Translational Medicine</source><volume>5</volume><elocation-id>205</elocation-id><pub-id pub-id-type="doi">10.21037/atm.2017.03.64</pub-id><pub-id pub-id-type="pmid">28603720</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulasne</surname><given-names>D</given-names></name><name><surname>Deheuninck</surname><given-names>J</given-names></name><name><surname>Lourenco</surname><given-names>FC</given-names></name><name><surname>Lamballe</surname><given-names>F</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Leroy</surname><given-names>C</given-names></name><name><surname>Puchois</surname><given-names>E</given-names></name><name><surname>Moumen</surname><given-names>A</given-names></name><name><surname>Maina</surname><given-names>F</given-names></name><name><surname>Mehlen</surname><given-names>P</given-names></name><name><surname>Fafeur</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Proapoptotic function of the MET tyrosine kinase receptor through caspase cleavage</article-title><source>Molecular and Cellular Biology</source><volume>24</volume><fpage>10328</fpage><lpage>10339</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.23.10328-10339.2004</pub-id><pub-id pub-id-type="pmid">15542841</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyner</surname><given-names>JW</given-names></name><name><surname>Fletcher</surname><given-names>LB</given-names></name><name><surname>Wang</surname><given-names>EQ</given-names></name><name><surname>Yang</surname><given-names>WF</given-names></name><name><surname>Rutenberg-Schoenberg</surname><given-names>ML</given-names></name><name><surname>Beadling</surname><given-names>C</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Deininger</surname><given-names>MW</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name><name><surname>Loriaux</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>MET receptor sequence variants R970C and T992I lack transforming capacity</article-title><source>Cancer Research</source><volume>70</volume><fpage>6233</fpage><lpage>6237</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0429</pub-id><pub-id pub-id-type="pmid">20670955</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uchikawa</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>GY</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Bai</surname><given-names>XC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural basis of the activation of c-MET receptor</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>4074</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-24367-3</pub-id><pub-id pub-id-type="pmid">34210960</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uehara</surname><given-names>Y</given-names></name><name><surname>Minowa</surname><given-names>O</given-names></name><name><surname>Mori</surname><given-names>C</given-names></name><name><surname>Shiota</surname><given-names>K</given-names></name><name><surname>Kuno</surname><given-names>J</given-names></name><name><surname>Noda</surname><given-names>T</given-names></name><name><surname>Kitamura</surname><given-names>N</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor</article-title><source>Nature</source><volume>373</volume><fpage>702</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1038/373702a0</pub-id><pub-id pub-id-type="pmid">7854453</pub-id></element-citation></ref><ref id="bib124"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ujiie</surname><given-names>H</given-names></name><name><surname>Tomida</surname><given-names>M</given-names></name><name><surname>Akiyama</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>Y</given-names></name><name><surname>Okada</surname><given-names>D</given-names></name><name><surname>Yoshino</surname><given-names>N</given-names></name><name><surname>Takiguchi</surname><given-names>Y</given-names></name><name><surname>Tanzawa</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer</article-title><source>Anticancer Research</source><volume>32</volume><fpage>3251</fpage><lpage>3258</lpage><pub-id pub-id-type="pmid">22843899</pub-id></element-citation></ref><ref id="bib125"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Umeki</surname><given-names>K</given-names></name><name><surname>Shiota</surname><given-names>G</given-names></name><name><surname>Kawasaki</surname><given-names>H</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Clinical significance of c-met oncogene alterations in human colorectal cancer</article-title><source>Oncology</source><volume>56</volume><fpage>314</fpage><lpage>321</lpage><pub-id pub-id-type="doi">10.1159/000011985</pub-id><pub-id pub-id-type="pmid">10343196</pub-id></element-citation></ref><ref id="bib126"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>T</given-names></name><name><surname>Antoine</surname><given-names>M</given-names></name><name><surname>Ruppert</surname><given-names>AM</given-names></name><name><surname>Fallet</surname><given-names>V</given-names></name><name><surname>Duruisseaux</surname><given-names>M</given-names></name><name><surname>Giroux Leprieur</surname><given-names>E</given-names></name><name><surname>Poulot</surname><given-names>V</given-names></name><name><surname>Rabbe</surname><given-names>N</given-names></name><name><surname>Sclick</surname><given-names>L</given-names></name><name><surname>Beau-Faller</surname><given-names>M</given-names></name><name><surname>Lacave</surname><given-names>R</given-names></name><name><surname>Lavole</surname><given-names>A</given-names></name><name><surname>Cadranel</surname><given-names>J</given-names></name><name><surname>Wislez</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Blood vessel invasion is a major feature and a factor of poor prognosis in sarcomatoid carcinoma of the lung</article-title><source>Lung Cancer</source><volume>85</volume><fpage>276</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2014.06.004</pub-id><pub-id pub-id-type="pmid">24997135</pub-id></element-citation></ref><ref id="bib127"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waqar</surname><given-names>SN</given-names></name><name><surname>Morgensztern</surname><given-names>D</given-names></name><name><surname>Sehn</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Met mutation associated with responsiveness to crizotinib</article-title><source>Journal of Thoracic Oncology</source><volume>10</volume><fpage>e29</fpage><lpage>e31</lpage><pub-id pub-id-type="doi">10.1097/JTO.0000000000000478</pub-id><pub-id pub-id-type="pmid">25898962</pub-id></element-citation></ref><ref id="bib128"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidner</surname><given-names>KM</given-names></name><name><surname>Sachs</surname><given-names>M</given-names></name><name><surname>Riethmacher</surname><given-names>D</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-of-function mutations of the met receptor in epithelial cells</article-title><source>PNAS</source><volume>92</volume><fpage>2597</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.7.2597</pub-id><pub-id pub-id-type="pmid">7708691</pub-id></element-citation></ref><ref id="bib129"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Woolf</surname><given-names>AS</given-names></name><name><surname>Kolatsi-Joannou</surname><given-names>M</given-names></name><name><surname>Hardman</surname><given-names>P</given-names></name><name><surname>Andermarcher</surname><given-names>E</given-names></name><name><surname>Moorby</surname><given-names>C</given-names></name><name><surname>Fine</surname><given-names>LG</given-names></name><name><surname>Jat</surname><given-names>PS</given-names></name><name><surname>Noble</surname><given-names>MD</given-names></name><name><surname>Gherardi</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Roles of hepatocyte growth factor/scatter factor and the met receptor in the early development of the metanephros</article-title><source>The Journal of Cell Biology</source><volume>128</volume><fpage>171</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1083/jcb.128.1.171</pub-id><pub-id pub-id-type="pmid">7822413</pub-id></element-citation></ref><ref id="bib130"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>SB</given-names></name><name><surname>Um</surname><given-names>SL</given-names></name><name><surname>Peek</surname><given-names>VL</given-names></name><name><surname>Stephens</surname><given-names>JR</given-names></name><name><surname>Zeng</surname><given-names>W</given-names></name><name><surname>Konicek</surname><given-names>BW</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Manro</surname><given-names>JR</given-names></name><name><surname>Wacheck</surname><given-names>V</given-names></name><name><surname>Walgren</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping</article-title><source>Investigational New Drugs</source><volume>36</volume><fpage>536</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1007/s10637-017-0545-x</pub-id><pub-id pub-id-type="pmid">29188469</pub-id></element-citation></ref><ref id="bib131"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Spitzer</surname><given-names>E</given-names></name><name><surname>Meyer</surname><given-names>D</given-names></name><name><surname>Sachs</surname><given-names>M</given-names></name><name><surname>Niemann</surname><given-names>C</given-names></name><name><surname>Hartmann</surname><given-names>G</given-names></name><name><surname>Weidner</surname><given-names>KM</given-names></name><name><surname>Birchmeier</surname><given-names>C</given-names></name><name><surname>Birchmeier</surname><given-names>W</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland</article-title><source>The Journal of Cell Biology</source><volume>131</volume><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1083/jcb.131.1.215</pub-id><pub-id pub-id-type="pmid">7559778</pub-id></element-citation></ref><ref id="bib132"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CQ</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>SQ</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>YW</given-names></name><name><surname>Kong</surname><given-names>SX</given-names></name><name><surname>Liu</surname><given-names>RM</given-names></name><name><surname>Wang</surname><given-names>SM</given-names></name><name><surname>Lv</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>MCP-1 stimulates MMP-9 expression via ERK 1/2 and p38 MAPK signaling pathways in human aortic smooth muscle cells</article-title><source>Cellular Physiology and Biochemistry</source><volume>34</volume><fpage>266</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1159/000362997</pub-id><pub-id pub-id-type="pmid">25033895</pub-id></element-citation></ref><ref id="bib133"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Pang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ou</surname><given-names>Q</given-names></name><name><surname>Tian</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer</article-title><source>Respiratory Research</source><volume>24</volume><elocation-id>28</elocation-id><pub-id pub-id-type="doi">10.1186/s12931-023-02329-1</pub-id><pub-id pub-id-type="pmid">36698189</pub-id></element-citation></ref><ref id="bib134"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaffaroni</surname><given-names>D</given-names></name><name><surname>Spinola</surname><given-names>M</given-names></name><name><surname>Galvan</surname><given-names>A</given-names></name><name><surname>Falvella</surname><given-names>FS</given-names></name><name><surname>Pazzaglia</surname><given-names>S</given-names></name><name><surname>Saran</surname><given-names>A</given-names></name><name><surname>Mancuso</surname><given-names>MT</given-names></name><name><surname>Galbiati</surname><given-names>F</given-names></name><name><surname>Pignatiello</surname><given-names>C</given-names></name><name><surname>Cabrera</surname><given-names>W</given-names></name><name><surname>Ibanez</surname><given-names>O</given-names></name><name><surname>Manenti</surname><given-names>G</given-names></name><name><surname>Dragani</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis</article-title><source>Oncogene</source><volume>24</volume><fpage>1084</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1208324</pub-id><pub-id pub-id-type="pmid">15592501</pub-id></element-citation></ref><ref id="bib135"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping</article-title><source>Lung Cancer</source><volume>113</volume><fpage>69</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2017.09.006</pub-id><pub-id pub-id-type="pmid">29110851</pub-id></element-citation></ref></ref-list></back></article>